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5ABBREVIATIONS
ANOVA analysis of variance
AUC(0-t) area under the concentration-time curve from 0 to t hours
AUC(0-∞) total area under the concentration-time curve
CFFT critical flicker fusion test
Cloral oral clearance
Cmax peak concentration in serum or plasma
CNS central nervous system
CYP cytochrome P-450 enzyme
CV coefficient of variation
DSST digit symbol substitution test
ECG electrocardiogram
ERMBT erythromycin breath test
GABA gamma-aminobutyric acid
HMG-CoA 3-hydroxy-3-methylglutaryl-coenzyme A
HPLC high performance liquid chromatography
5-HT serotonin
kel elimination rate constant
LC-MS-MS liquid chromatography-tandem mass spectrometry
MDR multiple drug resistance
mRNA messenger ribonucleic acid
OC oral contraceptive steroid
P-gp P-glycoprotein
QTc heart rate-corrected QT interval
REA radioenzyme inhibition assay
SD standard deviation
SEM standard error of the mean
t½ half-life
t.i.d. three times a day
tmax time of peak concentration
VAS visual analogue scale
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7ABSTRACT
About ten years ago, grapefruit juice was observed to increase the plasma concentrations and
effects of felodipine. Since then, grapefruit juice has been found to interact with more than 20
different drugs. However, many factors affecting the susceptibility of drugs to interaction with
grapefruit juice are still unknown. In this series of investigations, the potential of grapefruit
juice to interact with the CYP3A4 substrates buspirone, cisapride, simvastatin, atorvastatin, and
pravastatin was studied in healthy human volunteers in randomized cross-over studies. In
addition, the effect of grapefruit juice dose in pharmacokinetic interaction and the duration of
grapefruit juice effect were studied, with triazolam and simvastatin, respectively, as the model
drugs. In each study, 10 to 12 volunteers participated. Subjects ingested grapefruit juice 200 ml
or water (control) t.i.d. for 2 days and then received a single dose of study drug with grapefruit
juice or water. The effect of dose of grapefruit juice was studied by giving the volunteers the
study drug with 200 ml water, normal or double-strength grapefruit juice,  or on the third day of
double-strength grapefruit juice, 200 ml t.i.d. Duration of effect of grapefruit juice was studied
by administering the study drug after multiple-dose grapefruit juice (200 ml t.i.d. for 3 days) or
1, 3, or 7 days after the last dose of multiple-dose grapefruit juice. Following administration of
the study drug, timed blood samples were taken for up to 12 to 72 hours for determination of
plasma or serum drug concentrations by means of gas and liquid chromatographic, mass
spectrometric, or radioenzyme inhibition assay.
Grapefruit juice substantially increased plasma concentrations of buspirone. The AUC of
buspirone was increased by grapefruit juice about 9-fold (p < 0.01). The increased buspirone
plasma concentrations were associated with increased subjective drug effect. The
pharmacokinetics of cisapride were considerably affected by grapefruit juice. The AUC of
cisapride was increased by about 140% by grapefruit juice (p < 0.01), but it did not enhance the
effect of a single dose of cisapride on the QTc interval. Grapefruit juice increased the AUC of
simvastatin and simvastatin acid about 16-fold (p < 0.05) and 7-fold (p < 0.01), respectively.
The AUC of atorvastatin acid was increased by about 150% (p < 0.01). The AUC of 2-
hydroxyatorvastatin acid, the main active metabolite of atorvastatin, was decreased by
grapefruit juice (p < 0.01). Grapefruit juice did not affect the pharmacokinetics of pravastatin.
All of these interactions were subject to large interindividual variation. A single dose of either
normal- or double-strength grapefruit juice and the multiple dose of double-strength grapefruit
8juice increased triazolam AUC by about 50% (p < 0.01) and 140% (p < 0.001), respectively.
Multiple-dose ingestion of grapefruit juice affected triazolam pharmacokinetics significantly
more than did a single dose of normal- or double-strength grapefruit juice (p < 0.001). The
elimination t½ of triazolam was significantly prolonged by multiple dose (p < 0.001), but not by
a single dose of grapefruit juice. Triazolam effects were increased by multiple-dose grapefruit
juice. The effect of grapefruit juice on the AUC of simvastatin was approximately one-tenth of
its maximum 24 hours after termination of repeated intake of grapefruit juice. The effect of
grapefruit juice on the pharmacokinetics of simvastatin disappeared within 3 to 7 days.
It is probable that in these studies the pharmacokinetic interactions between grapefruit juice and
CYP3A4 substrates mostly occurred during their first pass, because both the Cmax and AUC
values substantially increased. However, it appears that the systemic elimination as well may be
inhibited by multiple-dose grapefruit juice, as evidenced by significantly increased elimination
t½ of some of the drugs. Susceptibility of CYP3A4 substrates to interaction with grapefruit
juice reflects the extent of their first-pass metabolism. This long-lasting effect of grapefruit
juice is in line with the proposal that the mechanism of action of grapefruit juice is irreversible
inactivation of CYP3A4. However, other mechanisms such as modulation of function of P-
glycoprotein may have contributed. Large interindividual variation in pharmacokinetics of the
CYP3A4 substrates observed in these studies makes prediction of the magnitude of interaction
for an individual difficult. Concomitant ingestion of grapefruit juice with CYP3A4 substrates
with extensive first-pass metabolism and a narrow therapeutic range can increase the risk for
adverse effects of these drugs.
9INTRODUCTION
Drugs and other exogenous lipophilic compounds usually have to be metabolized before they
can be excreted from the body. This metabolism occurs by phase I and phase II reactions. In
phase I, the majority of drugs undergo biotransformation reactions that are generally mediated
by CYP enzymes, oxidative reactions being the most common. In phase II reactions, drug
molecules or their metabolites are usually conjugated. There is considerable interindividual
variation in activity of drug-metabolizing enzymes caused by both genetic and exogenous
factors. Concomitant administration of two or more drugs may alter their pharmacokinetics,
especially if they are metabolized by the same isoenzyme. There are many well-characterized
pharmacokinetic drug-drug interactions which can have highly significant clinical
consequences due to increased therapeutic effects or toxicity (Olkkola et al. 1993; Neuvonen
and Jalava 1996). Smoking and dietary factors can also alter significantly drug metabolism
(Conney et al. 1977; Grygiel and Birkett 1981; Singh 1999).
A serendipitous finding about 10 years ago in a clinical drug study, when grapefruit juice was
used to mask the taste of ethanol, led to the discovery of a grapefruit juice-felodipine
interaction. Felodipine is a dihydropyridine calcium-channel antagonist used for the treatment
of hypertension. Simultaneous administration of felodipine with a single glass of grapefruit
juice increased significantly the plasma concentration of felodipine and also increased its
hypotensive effect (Bailey et al. 1991). Since then, grapefruit juice has been shown to increase
plasma concentrations of several drugs, e.g., cyclosporin, midazolam, and terfenadine (Yee et
al. 1995; Kupferschmidt et al. 1995; Benton et al. 1996). In some instances, coadministration of
drugs with grapefruit juice has increased significantly the intensity and duration of effects of
these drugs. Most of the drugs reported to be susceptible to interaction with grapefruit juice
have variable oral bioavailability due to moderate or extensive first-pass metabolism. Almost
exclusively, these drugs are also substrates for CYP3A4, the most important drug-metabolizing
member of the CYP enzyme family that participates in the metabolism of about 50% of drugs
(Wrighton et al. 1992). However, relatively few published studies adress the question of the
dose-relationship of the grapefruit juice effect and duration of the effect of grapefruit juice. In
this series of investigations, the purpose was to study to what degree grapefruit juice can
interfere with the pharmacokinetics of drugs metabolized to varying degrees by CYP3A4, and
also to discover factors governing these interactions.
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REVIEW OF THE LITERATURE
1. Drug metabolism and interactions
1.1. Cytochrome P450 (CYP) enzymes and drug interactions
Drug molecules are often lipophilic, which allows their absorption from the gastrointestinal
tract and also their entry to the site of action, e.g., in the brain. Excretion of drugs and other,
perhaps toxic, lipophilic foreign compounds (xenobiotics) from the body in the bile and urine is
facilitated by metabolic reactions that transform them into being more hydrophilic, i.e., soluble
in water (Morselli 1995). These reactions comprise oxidation, hydroxylation, dealkylation, and
reduction. They are called phase I reactions. In phase II reactions, drug molecules or their
metabolites are conjugated with endogenous molecules such as glucuronate, sulfate, acetate, or
an amino acid. Usually drugs undergo reactions of both phases before their elimination. Drug
metabolism occurs mainly in the liver, although organs such as the gastrointestinal tract,
kidneys, and lungs also contribute to biotransformation reactions (Krishna and Klotz 1994).
Orally administered drugs must traverse the intestinal wall, the hepatic portal system, and the
liver before they reach the systemic circulation. If a drug is subject to extensive
biotransformation in the liver, only a fraction of its dose will reach the systemic circulation and,
ultimately, its site of action. This phenomenon is referred to as first-pass metabolism. By the
term extraction ratio is meant the fraction of drug removed from the blood during a single
transit through the liver. Correspondingly, drugs that undergo extensive first-pass metabolism
have high extraction ratios (i.e. > 0.7). First-pass metabolism can reduce in a significant way
the bioavailability of some drugs, despite complete absorption. As well as in the liver, orally
administered drugs can be subject to metabolism in the intestinal wall before they reach the
systemic circulation. It has been shown that for some drugs (mostly CYP3A4 substrates)
presystemic metabolism in the intestine can be a significant determinant of their bioavailability
(Paine et al. 1996; Thummel et al. 1996).
Drugs and other xenobiotics are mainly transformed in phase I reactions by human cytochrome
P-450 enzymes (CYP enzymes). CYP enzymes constitute an enzyme superfamily of hem-
containing mono-oxygenases, which have an absorption maximum at wavelength 450 nm in
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the presence of carbon monoxide; hence the name P-450. Besides drug metabolism, CYP
enzymes are important in the synthesis and metabolism of different endogenous compounds
like steroid hormones, fatty acids, arachidonic acid, and bile acids. The classification of CYP
enzymes is based on homology of their deduced amino acid sequences (Nelson et al. 1996).
Within a single CYP family, enzymes show amino acid sequence homology greater than 40%
and are denoted in the nomenclature by a common Arabic number (e. g., CYP3). Within one
subfamily, enzymes share a homology greater than 55% and are denoted by a common letter (e.
g., CYP3A). Single isoforms are labeled with a second Arabic number (e. g., CYP3A4).
In humans, 14 CYP gene families are known to date, of which the first three families are
important in the metabolism of drugs and xenobiotics. The other CYP gene families are
responsible for the biotransformation of endogenous compounds like steroids.
Human CYP1A1 demonstrates almost 70% sequence similarity to CYP1A2. In humans,
CYP1A1 has been found almost exclusively in extrahepatic tissues such as lung, small
intestine, and placenta (Pasanen et al. 1988; Shimada et al. 1992; McLemore et al. 1994).
Without induction, it is often not expressed. It is induced by cigarette smoke and polycyclic
aromatic hydrocarbons (PAHs) (Wrighton and Stevens 1992). A prototype substrate for
CYP1A1 is benzo(a) pyrene (Shimada et al. 1989). Unlike CYP1A1, in humans CYP1A2
appears to be present only in the liver, where it represents 10 to 15% of the total amount of
CYP (Shimada et al. 1994). It catalyzes 3-demethylation of caffeine and is also responsible for
L-demethylation of theophylline and O-de-ethylation of phenacetin (Butler et al. 1989; Sesardic
et al. 1990; Brosen et al. 1993). Most substrates of CYP1A1 appear also to be substrates of
CYP1A2 (Tassaneeyakul et al. 1993), which is induced by cigarette smoke, physical exercise,
charcoal broiled meat, or cruciferous vegetables (Wrighton and Stevens 1992). Human
CYP1A2 is inhibited by α-naphtoflavone, 7-ethoxycoumarin, furafylline, and fluvoxamine
(Tassaneeyakul et al. 1993; Jeppesen et al. 1996).
In humans at least four members of the CYP2C subfamily are expressed, and they participate in
drug metabolism, namely, CYP2C8, CYP2C9, CYP2C18, and CYP2C19. After the CYP3A
subfamily, the CYP2C enzymes form the second largest CYP subfamily in human liver,
comprising 20% of its total amount of CYP protein (Shimada et al. 1994). CYP2C enzymes are
also expressed to a minor extent in the small intestine (Zhang et al. 1999). CYP2C8 catalyzes
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the biotransformation of retinal, retinoic acid, and taxol (Leo et al. 1989; Rahman et al. 1994).
CYP2C9 metabolizes phenytoin, tolbutamide, warfarin, and NSAIDs (Knodell et al. 1987;
Veronese et al. 1991; Rettie et al. 1992; Leemann et al. 1993). Both CYP2C8 and CYP2C9 are
induced by rifampicin and phenytoin. CYP2C9 is inhibited by sulphaphenazole, fluconazole,
amiodarone, and metronidazole (Back 1988). CYP2C18 catalyzes biotransformation of such
drugs as diazepam. There is large interindividual variability in drug-metabolizing capacity
mediated by CYP2C19 that is caused by genetic polymorphisms. About 3% of Caucasians and
20% of Asians are poor metabolizers of CYP2C19 substrates (Wedlund et al. 1984; Nakamura
et al. 1985). CYP2C19 metabolizes a wide variety of drugs, such as mephenytoin,
amitriptyline, imipramine, and diazepam (Breyer-Pfaff et al. 1992; Skjelbo et al. 1993;
Bertilsson et al. 1989). Fluvoxamine and fluoxetine are inhibitors of CYP2C19 (Jeppesen et al.
1996).
Expression of CYP2D6 has been shown to be determined by genetic polymorphisms
(Bertilsson 1995). About 7% of Caucasians and 1% of Asian populations are poor metabolizers
of CYP2D6 substrates. Although CYP2D6 constitutes only about 2% of the hepatic CYP
protein, it participates in the biotransformation of a range of widely used drugs such as tricyclic
antidepressants, neuroleptics, and β-blockers (Cholerton et al. 1992). CYP2D6 is not inducible,
but can be inhibited by such drugs as quinidine, paroxetine and fluoxetine (Inaba et al. 1986;
Jeppesen et al. 1996).
The subfamily CYP3A consists of at least three functional  human genes: CYP3A4, CYP3A5,
and CYP3A7. It comprises about 30% of the total hepatic protein and is also the most prevalent
CYP enzyme in the small intestine (Shimada et al. 1994; Paine et al. 1997). In humans,
CYP3A4 is both qualitatively and quantitatively the most important CYP isoform in drug
metabolism. Besides the liver, it is abundantly expressed in the duodenum, jejunum, and ileum
where it represents a respective 63%, 49%, and 88% of  total CYP protein (Paine et al. 1997). It
has been shown that the cDNAs of intestinally and hepatically expressed forms of human
CYP3A4 are identical (Lown et al. 1998); however, they are possibly not co-regulated (Lown et
al. 1994). An at least 10-fold interindividual variation has been found in the amount of
CYP3A4 both in the liver and in the small intestine (Lown et al. 1994). The molecular basis for
this wide interindividual variation in expression and function has thus far remained
unexplained. In some but not all studies, females have shown greater CYP3A4 activity than
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males (Watkins et al. 1989; Kashuba et al. 1998). Some studies suggest that the phases of the
menstrual cycle have no effect on the pharmacokinetics of CYP3A4 substrates (Kashuba et al.
1998; Kamimori et al. 2000).
CYP3A5 shows a sequence homology of 84% with CYP3A4, but unlike the latter it is
polymorphically expressed. In the majority of humans, CYP3A5 is expressed in the liver and
small intestine at low levels, but it is the major CYP3A in the colon (Kolars et al. 1994).
CYP3A5 has relatively widely overlapping substrate specificity with CYP3A4 (Wrighton et al.
1990).
CYP3A7 is the major CYP3A isoform in the fetal liver, but CYP3A7 mRNA has been found
also in adult livers (Hakkola et al. 1998).
In humans, CYP3A4 catalyzes the biotransformation of a very large number of drugs that are
mostly lipohilic but otherwise often very dissimilar structurally. The list of CYP3A4 substrates
includes, from different therapeutic areas: midazolam (Gorski et al. 1994), triazolam (Kronbach
et al. 1989), cyclosporin (Kronbach et al. 1988), diltiazem (Pichard et al. 1990),
dihydropyridine calcium-channel antagonists (Guengerich et al. 1991), lovastatin (Wang et al.
1991), simvastatin (Prueksaritanont et al. 1997), cisapride (Bohets et al. 2000), erythromycin
(Hunt et al. 1992), saquinavir (Fitzsimmons and Collins 1997), and itraconazole (Ducharme et
al. 1995a). CYP3A4 is inhibited for instance by such drugs as itraconazole (Back and Tjia
1991; Olkkola et al. 1994; Neuvonen and Jalava 1996), erythromycin (Olkkola et al. 1993),
diltiazem (Backman et al. 1994), verapamil, and ritonavir (Eagling et al. 1997). Prototype
inducers of CYP3A4 include rifampicin, phenytoin, and carbamazepine (Backman et al. 1996;
Bertilsson et al. 1997; Capewell et al. 1988).
1.2. Mechanisms of CYP inhibition
Drugs and chemicals may cause reversible or irreversible inhibition of CYP enzymes and thus
prevent biotransformation of substrates. In reversible inhibition, a preferentially lipophilic
compound  binds tightly within the active site of the enzyme. This prevents binding of other
substrate molecules to active hydrophobic regions on the CYP apoprotein or oxygen activation
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by CYP heme, both actions resulting in transient although sometimes potent inhibition of
enzyme activity (Murray 1999). Competitive inhibitors are often but not necessarily substrates
for the enzyme they inhibit. Typical competitive inhibitors of CYP enzymes include the
imidazole antifungals ketoconazole and itraconazole and the protease inhibitor, ritonavir (Back
and Tjia 1991; Eagling et al. 1997)
Irreversible inhibition of CYP enzymes, also called mechanism-based inhibition, can be
divided into two categories: autocatalytic inactivation and metabolite intermediate (MI)-
complexation. Autocatalytic inactivation or suicide inhibition takes place when a reactive drug
metabolite, formed in previous catalytic steps by a CYP enzyme, binds to this enzyme and
alters its structure, resulting in irreversible loss of function. This can lead to rapid destruction
of enzyme protein. Gestodene (Guengerich 1990a), ethinyl estradiol (Guengerich 1988),
spironolactone (Decker et al. 1989), furanocoumarin methoxsalen (Tinel et al. 1987), and
furafylline (Kunze and Trager 1993) are examples of suicide inhibitors. Alkylamines are
probably the most significant class of compounds able to cause irreversible inhibition of CYPs
through complexation of a metabolite intermediate with an enzyme. Putative oxidized
metabolite intermediates include nitroso analogues of substrate molecules. These analogues
bind tightly to the CYP heme, preventing oxygen binding and activation. Elicited inhibition can
be protracted although CYP protein is not degraded. The macrolide antibiotics erythromycin
and troleandomycin are known inhibitors of CYPs that form MI-complexes (Periti et al. 1992).
1.3. P-glycoprotein
P-glycoproteins (P-gp) are plasma membrane glycoproteins that belong to the superfamily of
ATP-binding cassette (ABC) transporters (Preiss 1998). They mediate the transport of
xenobiotics and endogenous substrates from the inner to the outer surface of cell membranes.
P-glycoproteins can be expressed in the luminal surfaces of the small and large intestine, biliary
tract, hepatocytes, endothelial cells that contribute to the blood brain barrier, and the proximal
tubule of the kidneys (Lum and Gosland 1995). A possible physiological role for P-gp is to
secrete endogenous and xenobiotic compounds and thus contribute to protective barrier
mechanisms. P-gp has also been found to be a cause for MDR (multiple drug resistance) as it is
overexpressed in cancer cells that are resistant to chemotherapeutic agents. In these cells, P-gp
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functions as an efflux pump that decreases intracellular drug concentrations and cytotoxicity
(Lum and Gosland 1995). P-gp and CYP3A4 have widely overlapping substrate specificity
(Wacher et al. 1995). Many of the inhibitors and inducers of CYP3A4 are also capable of
altering the activity of P-gp (Relling 1996; Schuetz et al. 1996).
2. Grapefruit juice
2.1. Effects of grapefruit juice on drug metabolism and its mechanism of action
Approximately 10 years ago, Bailey et al. reported on the first grapefruit juice-drug interaction
observed between grapefruit juice and felodipine, a dihydropyridine Ca-channel blocker (Bailey
et al. 1991). This was recognized as a chance finding during an ethanol-felodipine interaction
study. In a study with six borderline hypertensive patients, 250 ml double-strength grapefruit
juice, but not orange juice, increased three-fold the mean plasma felodipine area under the
curve (AUC) compared with the AUC achieved with water (Bailey et al. 1991). Grapefruit
juice elevated the peak plasma concentration (Cmax) of felodipine, whereas the elimination t½
remained unchanged. The AUC of dehydrofelodipine, the primary metabolite of felodipine,
was also elevated by grapefruit juice. However, the dehydrofelodipine/felodipine AUC ratio
was lower with grapefruit juice than with water.
Felodipine is usually completely absorbed from the gastrointestinal tract (Edgar et al. 1985).
However, due to its presystemic metabolism, its absolute bioavailability is about 15%, with
considerable interindividual variation. Oxidation of felodipine into dehydrofelodipine and that
of dehydrofelodipine into a secondary metabolite are both catalyzed by the CYP3A4 that is
abundantly expressed both in the apical enterocytes of the small bowel and in the hepatocytes
of the liver. Thus, the results from Bailey et al. indicate that grapefruit juice inhibits both the
primary metabolic pathway of felodipine and the subsequent metabolic pathway of
dehydrofelodipine. In addition to the plasma concentrations of felodipine, also the
pharmacodynamic effects of felodipine: blood pressure reduction, heart rate increase, and
frequency of vasodilatation-related adverse effects, were greater during the grapefruit juice
phase (Bailey et al. 1991). Because grapefruit juice did not alter intravenous felodipine
pharmacokinetics, it was hypothesized that the interaction with grapefruit juice results from
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inhibition of presystemic drug metabolism (Lundahl et al. 1997). Thus, it seemed that the main
mechanism of action of grapefruit juice is inhibition of the CYP3A4-mediated first-pass
metabolism in the intestinal wall.
Recently, results of an investigation by Lown et al. (1997) gave further support to this
hypothesis. In this in vivo study, consumption of grapefruit juice t.i.d. for 5 days resulted in a
mean 62% reduction in small intestinal enterocyte CYP3A4 protein content and a 3-fold and 5-
fold increase in felodipine AUC and Cmax, respectively. In contrast, no changes occurred in
small-intestine levels of CYP3A4 mRNA, or liver CYP3A4 activity as measured by the
erythromycin breath test (ERMBT), in small-intestine levels of P-gp, or in colon levels of
CYP3A5. Further, intestinal CYP2D6 and CYP1A1 protein content remained unaltered. It was
concluded from the decreased CYP3A4 expression in the gut wall that the grapefruit-juice
effect is not only based on competitive inhibition. Because small intestine CYP3A4 mRNA
was not altered, grapefruit juice probably reduced CYP3A4 protein content by a post-
transcriptional mechanism, possibly by accelerated CYP3A4 degradation through mechanism-
based (suicide) enzyme inhibition. Thus, the restoration of CYP3A4 activity would require de
novo enzyme synthesis (Lown et al. 1997). This is in line with results of a study by Lundahl et
al. (1995) which showed the effect of a single dose of grapefruit juice on felodipine
pharmacokinetics to be still present, even when the juice was ingested 24 hours before the drug.
Although grapefruit juice did not affect concentrations of P-gp in the small intestine it may
modify in some other way the function of this transporter. Grapefruit juice components have
been shown to inhibit the P-gp function in Caco-2 cells in vitro, and it has also been suggested
that inhibition of P-gp may be responsible for the effect of grapefruit juice on cyclosporine
pharmacokinetics in vivo (Takanaga et al. 1998; Edwards et al. 1999).
2.2. Active ingredients in grapefruit juice
Grapefruit juice (Citrus paradisi) contains an abundance of structurally differing flavonoids,
several of which are found also in other plants and fruits. The most prevalent flavonoid in
grapefruit juice is naringin, which is responsible for the bitter taste, and the concentrations of
which are reported to range from 100 to 800 mg/l, but usually reach 200 mg/l to 500 mg/l in
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commercial grapefruit-juice preparations (Ameer et al. 1996; Hagen et al. 1965; Kupferschmidt
et al. 1995). Other flavonoids present mainly as glycosides in grapefruit juice include narirutin,
hesperidin, quercetin, kaempferol, and apigenin (Guengerich et al. 1990b).
Naringin and its aglycone naringenin are known competitive inhibitors of CYP3A4-mediated
drug metabolism in human liver microsomes (Guengerich et al. 1990b; Miniscalco et al. 1992).
This fact, together with the high content of naringin in grapefruit juice, led to the proposal that
this flavonoid is the active component. Moreover, naringin is absent from orange juice, which
leaves unaffected the pharmacokinetics of felodipine or cyclosporin (Bailey et al. 1991; Yee et
al. 1995). It is suggested that the aglycone form of naringin, naringenin, is produced from
naringin by enzymatic cleavage of the sugar moiety, possibly in the small intestine, and
subsequently is glucuronized (Fuhr and Kummert 1995). In vitro, naringenin is more potent as
an inhibitor of drug metabolism than is naringin. In in vivo studies, naringenin was not found in
plasma, and the amount excreted renally was small relative to the administered naringin dose,
whereas the amount of naringenin glucuronide was higher in plasma and urine. It was
suggested that the inhibitory effect of this grapefruit juice flavonoid localizes in the small
intestine. However, naringin administered as an aqueous solution or in an encapsulated
preparation in the amount found in grapefruit juice did not affect the pharmacokinetics of
dihydropyridines in vivo (Bailey et al. 1993a; Bailey et al. 1993b). Quercetin is another
flavonoid compound in grapefruit juice that acts as a potent CYP3A4 inhibitor in vitro.
However, it is not specific for grapefruit juice. Furthermore, in vivo it did not affect the
pharmacokinetics of nifedipine (Rashid et al. 1993).
Recently, it has been suggested that furanocoumarins (psoralens) are the active ingredients in
grapefruit juice. Edwards et al. (1996) demonstrated that 6’,7’-dihydroxybergamottin, the major
furanocoumarin in grapefruit juice (extractable in methylene chloride) can inhibit CYP3A4-
mediated 6β-hydroxytestosterone formation in rat microsomes. A subsequent study showed
that 6’,7’-dihydroxybergamottin causes a dose-dependent fall in human CYP3A4 catalytic
activity and immunoreactive CYP3A4 concentration (Schmiedlin-Ren et al. 1997). These
results are in line with those of the study of Lown et al. (1997), in which grapefruit juice caused
down-regulation of the small intestinal CYP3A4, probably due to suicide inhibition.
Furthermore, Schmiedlin-Ren et al. (1997) found that, although the concentration of 6’,7’-
dihydroxybergamottin in grapefruit juice varies significantly among different grapefruit juice
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preparations, it exceeds the IC50 for midazolam 1’-OH formation. Bailey et al. (1998)
performed a study in which grapefruit juice was separated into supernatant and particulate
fractions, which were then assayed for naringin and 6’,7’-dihydroxybergamottin. The amounts
of naringin and 6’,7’-dihydroxybergamottin were higher in the supernatant than in the
particulate fraction. However, after oral coadministration of felodipine with these fractions, the
particulate fraction had a significantly greater AUC for felodipine than did the supernatant
fraction. The authors concluded that neither naringin nor 6’,7’-dihydroxybergamottin is the
major active ingredient in grapefruit juice, although each may contribute to the interaction.
He et al. (1998) showed that bergamottin, a major furanocoumarin in grapefruit juice, may act
as a mechanism-based inhibitor of CYP3A4. The inhibition of CYP3A4 required metabolism
of bergamottin and appeared to involve modification of apoprotein rather than either
modification of the heme or heme fragmentation. Recently, it has been demonstrated that
grapefruit juice contains furanocoumarin dimers that are potent inhibitors of CYP3A4 (Fukuda
et al. 1997; Guo et al. 2000). Both competitive and mechanism-based inhibition seem to be
involved. Although the concentrations of these dimers plus an epoxide of bergamottin in
grapefruit juice are lower than those of the monomers (bergamottin or 6’,7’-
dihydroxybergamottin), their contributions to the interaction appear comparable, due to the
higher inhibitory potencies of the dimers relative to those of the monomers against microsomal
CYP3A activity (Guo et al. 2000). Furthermore, these furanocoumarins reside in the precipitate
of grapefruit juice, a fact in line with results observed in vivo (Bailey et al. 1998). The
grapefruit-juice effect seems to be dependent on the presence of all the furanocoumarin
components and is weaker if some of them are absent from the juice (Guo et al. 2000).
 2.3. Interactions between grapefruit juice and drugs
Almost exclusively, all drugs shown to have a pharmacokinetic interaction with grapefruit juice
are CYP3A4 substrates. In the first reported grapefruit juice-drug interaction, the drug under
study was felodipine. Since then, more grapefruit juice interaction studies have been conducted
with felodipine than with any other drug (Fuhr 1998; Bailey et al. 1998). In studies in which
felodipine has been coadministered with a single dose of grapefruit juice, the mean increase in
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the AUC of felodipine has ranged from 43 to 234% (Fuhr 1998; Edgar et al. 1992; Lundahl et
al. 1995). The mean increase in felodipine Cmax has ranged from 70 to 225%.
In all these studies, grapefruit juice has not affected the tmax in a consistent manner. The
elimination t½ of felodipine has usually not been changed by grapefruit juice. In those studies
where measured, grapefruit juice has increased concentrations of the main metabolite of
felodipine, dehydrofelodipine, although to a lesser degree than concentrations of the parent
compound (Edgar et al. 1992; Bailey et al. 1993a; Bailey et al. 1995).
In a study by Lown et al. (1997), repeated consumption of grapefruit juice increased the AUC
and Cmax of felodipine by 211% and 335%, respectively. Increased felodipine concentrations
due to ingestion of grapefruit juice have been associated with increased effects of felodipine.
Thus, a pronounced blood pressure-lowering or heart rate-increasing effect of felodipine, or
both have been observed when hemodynamic monitoring has been performed (Bailey et al.
1991; Edgar et al. 1992). Coadministration of felodipine with grapefruit juice has also resulted
in increased incidence of adverse effects such as headache and flushing (Edgar et al. 1992;
Bailey et al. 1991).
In addition to felodipine, some other dihydropyridine calcium-channel antagonists have been
found to interact significantly with grapefruit juice. The Cmax and AUC of nisoldipine were
increased by 306% and 98%, respectively, by double-strength grapefruit juice 250 ml (Bailey et
al. 1993b). High plasma concentrations of nisoldipine with grapefruit juice did not result in
significant effects on blood pressure and produced only a slightly higher heart rate than did its
administration with water at 4 hours. The AUC of nifedipine after coadministration with
grapefruit juice was 134% of that with water (Bailey et al. 1991). Pharmacodynamic effects of
nifedipine were not changed significantly by grapefruit juice. A single dose of grapefruit juice
increased the AUC of nitrendipine by 106% (Soons et al. 1991) but did not alter its
hemodynamic effects. The Cmax and AUC of nimodipine were increased by 24% and 51% by a
single dose of grapefruit juice (Fuhr et al. 1998). Grapefruit juice 250 ml induced minor
changes in the pharmacokinetics of amlodipine but did not significantly affect its hemodynamic
effects (Josefsson et al. 1996). A single dose of grapefruit juice was not found to change
significantly the pharmacokinetics of verapamil (Zaidenstein et al. 1998). In a study by Sigusch
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et al. (1994), repeated doses of grapefruit juice (200 ml at 0, 2, 4, 8, and 12 h) did not
significantly change the AUC of diltiazem.
Cyclosporine is an immunosuppressive agent with a narrow therapeutic range and variable oral
bioavailability. It is a substrate for CYP3A4 (Kronbach et al. 1988). The majority of interaction
studies between cyclosporine and grapefruit juice have been performed with patients who take
cyclosporine on a regular basis. In young, healthy adults, a single dose of grapefruit juice
increased cyclosporine AUC and Cmax by 43% and 18%, respectively, after oral administration
(Yee et al. 1995). In a study by Ducharme et al. (1995b), a single dose of grapefruit juice given
twice increased cyclosporine AUC significantly after oral administration but not after
intravenous administration. Grapefruit juice given at 3-hour intervals for a period of 30 hours
increased the Cmax of cyclosporine by 22% in kidney transplant patients (Hollander et al. 1995).
In a study by Proppe et al. (1995), a mean increase of 77% and of 62% in the trough
concentrations of cyclosporine and its metabolites was observed after administration of
grapefruit juice 175 ml at an interval of 12 hours. Grapefruit juice increased significantly the
AUC of both cyclosporine and its metabolites in patients with autoimmune diseases (Ioannides-
Demos et al. 1997).
The non-sedating antihistamine terfenadine is a prodrug that has extensive CYP3A4-mediated
first-pass metabolism. The parent terfenadine can prolong the QT interval, which may result in
a life-threatening ventricular arrhythmia, torsades de pointes. In a study by Benton et al. (1996),
12 healthy volunteers received terfenadine 60 mg twice daily for 7 days. They were then
randomized to ingest grapefruit juice 250 ml with terfenadine twice daily or 2 hours after drug
for an additional 7 days. The AUC of the terfenadine acid metabolite increased 55% in the
simultaneous and 22% in the delayed group. The mean QT interval increased significantly in
the simultaneous group only. In another study, poor metabolizers of terfenadine received first
terfenadine 60 mg twice daily for 7 days and then terfenadine twice daily with grapefruit juice
(Honig et al. 1996). Coadministration of terfenadine with grapefruit juice resulted in
accumulation of parent terfenadine, and QT interval was significantly prolongated after
coingestion as compared with the baseline without terfenadine. In a randomized study in
healthy volunteers, a single dose of grapefruit juice raised the AUC and Cmax of terfenadine
carboxylate (Rau et al. 1997); the mean QT interval was not changed.
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Cisapride is a widely used gastrointestinal prokinetic agent that can cause prolongation of QT
interval. Coadministration of a single dose of cisapride with grapefruit juice increased cisapride
AUC by about 50% (Gross et al. 1999).
Midazolam and triazolam are short-acting benzodiazepine derivatives that have oral
bioavailability of 40 to 50%. Grapefruit juice 200 ml ingested 60 minutes and 15 minutes
before orally administered midazolam increased the AUC of midazolam by about 50% and
enhanced the pharmacodynamic effects of midazolam (Kupferschmidt et al. 1995). A single
dose of grapefruit juice increased triazolam AUC by approximately 50% and slightly increased
the effects of triazolam (Hukkinen et al. 1995). Vanakoski et al. (1996) concluded that
grapefruit juice may not have an important interaction with midazolam or triazolam.
Coadministration of estradiol derivatives with grapefruit juice has increased significantly
concentrations of the parent drug (Weber et al. 1996) or those of estrogen metabolites
(Schubert et al. 1995). Grapefruit juice has not affected the AUC of prednisone or prednisolone
(Hollander et al. 1995). However, methylprednisolone AUC was increased by 75% by
grapefruit juice (Varis et al. 2000).
The pharmacokinetics of lovastatin, an HMG-CoA reductase inhibitor, were considerably
changed after coadministration with grapefruit juice. The mean Cmax and AUC of lovastatin
were increased approximately 12-fold and 15-fold by grapefruit juice given t.i.d. for 3 days
(Kantola et al. 1998a). Saquinavir is a potent HIV protease inhibitor whose effectiveness is
limited by its low and variable oral bioavailability. Its AUC was increased by 50% by
grapefruit juice 200 ml given twice before administration of this drug (Kupferschmidt et al.
1998).
Grapefruit juice 300 ml increased the AUC(0-8) of carbamazepine by about 41% in epileptic
patients (Garg et al. 1998). Grapefruit juice has been found to reduce oral clearance of the
CYP1A2 substrate caffeine (Fuhr et al. 1993). However, pharmacokinetics of another CYP1A2
substrate, theophylline, remained unaffected (Fuhr et al. 1995).
 In the grapefruit juice-drug studies performed, type (fresh squeezed vs. reconstituted frozen
concentrate), concentration (normal vs. double strength), volume and scheme of administration
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(single dose vs. repeated doses) of grapefruit juice have varied. Also, with respect to
administration of study drug, the protocols have not been uniform. Most studies utilize a single
drug dose. However, in some studies drugs have been given to reach a steady state. This lack of
standardization of experimental conditions makes comparison of study results difficult.
3. CYP3A4 substrates studied
3.1. Buspirone
Buspirone is an anxiolytic agent structurally different from the benzodiazepines; it is an
azaspirodecanedione derivative. Buspirone has been shown to be equipotent as an anxiolytic
with benzodiazepines, but it does not produce sedation, motor impairment, or muscle
relaxation (Goldberg and Finnerty 1979; Cohn and Wilcox 1986; Seppälä et al. 1982;
Greenblatt et al. 1994). Buspirone lacks the potential for abuse or dependence in humans (Cole
et al. 1982; Balster 1990; Sellers et al. 1992). Its most common adverse-effects are dizziness,
drowsiness, gastrointestinal complaints, and headache (Newton et al. 1986).
It has been suggested that buspirone acts as a full or partial agonist for 5-HT1A receptors (Eison
and Temple 1986; Taylor 1988). Like serotonin, buspirone inhibits spontaneous firing of
serotonergic neurons in dorsal raphe nucleus and hippocampal slice preparations. In animal
studies, the anticonflict activity of buspirone has been shown to be abolished when the
serotonergic system is damaged. Unlike benzodiazepines, buspirone does not act by increasing
binding of GABA on the GABA receptors, and it has only a modest effect on the dopaminergic
system (Cimino et al. 1993; Taylor 1988). Buspirone can also increase the spontaneous firing
of noradrenergic neurons in the locus coerulaeus (Eison and Temple 1986).
Buspirone is rapidly and completely absorbed after oral administration (Mayol et al. 1985).
Time to reach the Cmax of buspirone is less than an hour (Gammans et al. 1986). Its systemic
bioavailability is low: less than 5% of an oral dose reaches the systemic circulation; this fact,
together with its good absorption, implies that it is subject to extensive first-pass metabolism
(Mayol et al. 1985). Buspirone is a lipophilic drug with an apparent volume of distribution of
5.3 l/kg. It is highly, over 95%, bound to plasma proteins, both albumin and α1-acid
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glycoprotein (Gammans et al. 1986). Its mean elimination t½ is about 2.5 hours (Mayol et al.
1985). No statistically significant differences in the pharmacokinetics of buspirone have been
found between any age- or sex groups (Gammans et al. 1986). Plasma concentrations of
buspirone are higher in patients with renal impairment than in healthy volunteers (Barbhaiya et
al. 1994), and patients with hepatic impairment have significantly increased AUC values and
significantly prolonged elimination half-lives compared to those of normal subjects (Barbhaiya
et al. 1994).
The major routes of biotransformation of buspirone include hydroxylation on the spiro and
pyrimidine rings and N-dealkylation of the butyl-substituted side chain (Jajoo et al. 1989; Jajoo
et al. 1990). Data concerning specific CYP enzymes involved in its biotransformation are
scarce, but the in vivo interaction profile of buspirone indicates that CYP3A4 is the major CYP
involved in its metabolism (Kivistö et al. 1997; Lamberg et al. 1998a). Plasma concentrations
of two primary metabolites of buspirone, 5-OH-buspirone and 1-PP (1-pyrimidinylpiperazine),
can exceed those of the parent drug (Gammans et al. 1986). Of the two metabolites, 5-OH-
buspirone seems pharmacologically inactive, but 1-PP is about 20% as active as its parent drug.
Relatively few pharmacokinetic studies involve the interactions of buspirone with other drugs.
In a study by Seppälä et al. (1982), alcohol does not interact significantly with buspirone. Food
has been shown to increase the AUC of buspirone by 80%, and it appears that this is due to
reduced first-pass metabolism, as the sum of buspirone and total (free and conjugated) 5-
hydroxybuspirone remained unchanged (Gammans et al. 1986). Gammans et al. (1987) studied
the effect of cimetidine on the pharmacokinetics of buspirone, finding no significant interaction
between these two drugs. Alprazolam and buspirone have no significant effects on each other’s
pharmacokinetics (Buch et al. 1993). Buspirone does not markedly affect the pharmacokinetics
of haloperidol (Huang et al. 1996). A 4-day pretreatment with itraconazole 200 mg/day or
erythromycin 1.5 g/day increased the AUC values of buspirone about 19-fold and 6-fold
(Kivistö et al. 1997). Lamberg and coworkers (1998a) found that a 3-day pretreatment with
verapamil 80 mg/day or diltiazem 60 mg/day increased the AUC of buspirone 3.4-fold and 5.5-
fold. Pretreatment with fluvoxamine moderately increased plasma buspirone concentrations
(Lamberg et al. 1998b), whereas the antihistamine terfenadine had no significant effect on its
pharmacokinetics (Lamberg et al. 1999). Rifampicin, a potent CYP-inducer, has reduced
buspirone AUC by about 90% (Lamberg et al. 1998c).
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3.2. Cisapride
Cisapride is a widely used gastrointestinal prokinetic agent indicated for the treatment of reflux
esophagitis, the symptomatic management of dyspepsia, and the relief of gastric symptoms
associated with diabetes mellitus, systemic sclerosis, and autonomic neuropathy (McCallum
1991). It is structurally a substituted piperidinyl benzamide that is chemically related to
metoclopramide (McCallum 1991). It has been suggested that cisapride interacts with 5-
hydroxytryptamine receptors. It differs from other prokinetic agents in that it has no
antidopaminergic properties. It has been suggested that it exerts its effect by increasing the
physiologic release of acetylcholine from postganglionic nerve-endings of the myenteric
plexus, which leads to improved propulsive motor activity of the esophagus, stomach, small
bowel, and large bowel (McCallum 1991).
Cisapride is well absorbed, and its peak plasma concentration is reached within 2 hours of oral
dosing (Van Peer et al. 1986). However, its absolute bioavailability is estimated at 40 to 50%,
indicating first-pass metabolism (Van Peer et al. 1986). Cisapride is 98% bound to plasma
proteins, and its volume of distribution is about 2 l/kg. Its elimination t½ has been reported to
be 7 to 10 h after oral dosing in healthy volunteers (McCallum 1991). Cisapride is extensively
metabolized, principally by N-dealkylation and aromatic hydroxylation (Van Peer et al. 1986):
oxidative N-dealkylation yields norcisapride, and aromatic hydroxylation yields 3-fluoro-4-
hydroxycisapride and 4-fluoro-2-hydroxycisapride (McCallum et al. 1988). In vitro,
biotransformation of cisapride is catalyzed mainly by CYP3A4 (Desta et al. 1999; Gotschall et
al. 1999; Bohets et al. 2000). Excretion of metabolites in urine and feces each represents 50%
of the dose (Van Peer et al. 1986).
Cisapride is generally well tolerated, gastrointestinal complaints being the most common
adverse effects (McCallum 1991). However, rare cases have been reported of serious
ventricular arrhythmias or long QT syndrome (Lewin et al. 1996; Sekkarie et al. 1997;
Wysowski and Bacsanyi 1996). A prolonged QT interval may result in torsades de pointes, a
ventricular tachycardia that can lead to ventricular fibrillation and be a cause of syncope and
sudden cardiac death. It has been demonstrated that cisapride can dose-dependently block
potassium channels and thus cause prolongation of the QT interval (Drolet et al. 1998). In most
of the cases of arrhythmia during treatment with cisapride, concomitant electrolyte
25
disturbances, cardiac abnormalities or comedications that increase cisapride concentrations
appear to have contributed (Wysowski and Bacsanyi 1996).
In 20 healthy preoperative patients, oral cisapride 20 mg increased the Cmax of controlled-
release morphine 20 mg by 56% (Rowbotham et al. 1991). Intravenous cisapride increased
significantly the AUC(0-1) for diazepam without any significant effect on AUC(0-48)
(Bateman 1986). In a study by Finet et al. (1991), cisapride increased the mean AUC(0-6) of
oral cyclosporine by 38%. Kirch et al. (1989) has reported that cisapride reduces the AUC(0-
24) of cimetidine and cimetidine increases the AUC(0-24) of cisapride. Ketoconazole,
itraconazole, and erythromycin, which are known CYP3A4 inhibitors, have been reported to
raise cisapride concentrations (Bedford and Rowbotham 1996). The manufacturer has warned
against concomitant use of cisapride with potent CYP3A4 inhibitors. A combination of
cisapride and clarithromycin has been reported to cause a 3-fold increase in cisapride
concentration and an average increase of 25 ms in QTc interval above the pretreatment value in
healthy volunteers (Van Haarst et al. 1998). In a study by Gross et al. (1999), 250 ml of normal-
strength grapefruit juice increased cisapride AUC(0-25) 1.5-fold. Recently, cisapride was
withdrawn from the market in the USA and in some other countries due to its arrhythmogenic
potential.
3.3. Simvastatin
Simvastatin is a cholesterol-lowering agent which inhibits HMG-CoA reductase, an enzyme
catalyzing a rate-limiting step in the biosynthesis of cholesterol in humans. It is a lipophilic
drug, about 1000-fold more lipophilic than pravastatin (Hamelin and Turgeon 1998).
Simvastatin is administered as an inactive lactone prodrug which is hydrolyzed by
carboxyesterases and nonenzymatically to the active agent simvastatin acid, a competitive
inhibitor of HMG-CoA reductase (Tang and Kalow 1995). It is extensively (61 to 85% in rats
and dogs) absorbed from the gastrointestinal tract when administered orally (Vickers et al.
1990a). A low-fat meal does not impair its absorption. In a study by Pentikäinen et al. (1992)
the peak inhibition of HMG-CoA reductase activity in healthy male volunteers occurred 2.5 h
after a single oral dose. Its bioavailability is low, due to extensive first-pass metabolism. About
7% of an oral simvastatin dose in dogs reached the systemic circulation unchanged (Vickers et
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al. 1990a). Its active metabolites are less lipophilic than the parent compound and tend to
remain in the liver, the organ responsible for synthesis of most endogenous cholesterol
(Vickers et al. 1990a). Both simvastatin and simvastatin acid are highly bound to plasma
proteins, at about 98 and 94% (Vickers et al. 1990a).
Simvastatin has several metabolites identified in human microsomal studies, of which 6’-
hydroxysimvastatin, 3’’-hydroxysimvastatin, 6’-hydroxymethylsimvastatin, and 6’-
hydroxycarbonylsimvastatin, when converted to their acid forms, are 50, 20, 90, and 40% as
active as simvastatin acid, respectively (Vickers et al. 1990b). The inactive lactone form of
simvastatin and its metabolites remain in a reversible equilibrium in plasma with their
corresponding active β-hydroxyacid forms (Vickers et al. 1990a; Vickers et al. 1990b). In
humans, biotransformation of simvastatin occurs mainly by the CYP3A4 expressed in the liver
and small intestine (Prueksaritanont et al. 1997), but unlike simvastatin, simvastatin acid is not
metabolized by mouse or rat liver microsomes. The elimination t½ of simvastatin is about 2
hours (Lennernäs and Fager 1997). Unchanged simvastatin and its metabolites are eliminated
via biliary excretion into the feces. In humans, 13% of a simvastatin dose has been collected in
urine (Mauro 1993).
Simvastatin is usually well tolerated, gastrointestinal adverse effects being the most common
reason for discontinuation of therapy. Mild transient elevations in serum transaminases are seen
in about 3.5% and sustained elevations in about 1% of patients receiving simvastatin. Clinically
symptomatic hepatitis or hepatic dysfunction is rare (Plosker and McTavish 1995). A
potentially severe but rare adverse effect of simvastatin is myopathy, which can proceed to
rhabdomyolysis. Increased risk for myopathy has been associated with concomitant
administration of simvastatin and cyclosporine (Meier et al. 1995). In addition to the
combination of simvastatin and cyclosporine, case reports exist of rhabdomyolysis being
associated with concomitant use of simvastatin and itraconazole (Segaert et al. 1996) or
mibefradil (Schmassmann-Suhijar et al. 1998). All the drugs used concomitantly with
simvastatin in these cases are inhibitors of CYP3A4 (Pelkonen et al. 1998; Welker et al.1998;
Wang et al. 1999). In kidney-transplant patients administered simvastatin, HMG-CoA
reductase inhibitory activity was elevated when they also received cyclosporin (Arnadottir et al.
1993). A 4-day pretreatment with itraconazole 200 mg/day increased the Cmax and AUC of total
simvastatin acid 17-fold and 19-fold, respectively (Neuvonen et al. 1998). In two different
27
studies, pretreatment with erythromycin 2.0 g per day for one week and 1.5 g per day for 2 days
increased the AUC of simvastatin 6.5-fold and 6.2-fold (Donahue et al. 1998; Kantola et al.
1998b). The calcium-channel antagonists verapamil and diltiazem are known inhibitors of
CYP3A4 (Renton 1985). A 2-day administration of verapamil increased the AUC of
simvastatin 4.6-fold (Kantola et al. 1998b). After a two-week treatment with diltizem 120 mg
twice a day, the AUC of simvastatin was increased 5-fold (Mousa et al. 2000).
3.4. Atorvastatin
Atorvastatin is a lipophilic inhibitor of HMG-CoA reductase administered as the calcium salt
of the active hydroxy acid form. The Cmax value of atorvastatin is reached within 2 to 4 hours
after oral administration (Lea and McTavish 1997). More than 40% of an oral dose of
atorvastatin is absorbed from the gastrointestinal tract. Its systemic bioavailability is
approximately 12% because of extensive metabolism during the first pass. Food decreases the
rate of atorvastatin absorption significantly but influences little the extent of absorption
(Radulovic et al. 1995). A greater than proportional increase in Cmax and AUC has been
observed across the 5- to 80-mg dose-range (Whitfield et al. 1993). Atorvastatin is 98% bound
to proteins in plasma (Lea and McTavish 1997). Its two active metabolites, 2-
hydroxyatorvastatin and 4-hydroxyatorvastatin, are formed in reactions catalyzed by CYP3A4.
These two metabolites are just as potent HMG-CoA reductase inhibitors as atorvastatin. About
70% of the AUC of inhibitory activity is accounted for by active metabolites. It has been
assumed that the long-lasting HMG-CoA reductase inhibitory activity of atorvastatin may
reflect the longer residence of atorvastatin or its active metabolites in the liver (Naoumova et
al. 1997). Atorvastatin acid has shown an elimination t½ of 11 to 24 hours, and an HMG-CoA
reductase inhibitory activity that ranges from 20 to 30 hours (Cilla et al. 1996; Lea and
McTavish 1997). Less than 2% of atorvastatin acid and its metabolites are excreted renally (Lea
and McTavish 1997). It has been suggested that atorvastatin may undergo enterohepatic
recycling (Gibson et al. 1996a). Age-related differences in atorvastatin pharmacokinetics have
been observed, possibly due to changes in hepatic clearance. Mean AUC and elimination t½
values have been about 26% greater and 36% longer in the elderly than in young adults (Gibson
et al. 1996a). Furthermore, modest gender-related differences in atorvastatin pharmacokinetics
have been reported, its mean AUC and elimination t½ being approximately 11% lower and 20%
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shorter in women than in men (Gibson et al. 1996a). Patients with hepatic impairment have
significantly higher concentrations of atorvastatin than do healthy volunteers, whereas renal
dysfunction does not alter the pharmacokinetics of atorvastatin (Gibson et al. 1996b; Stern et
al. 1997).
Atorvastatin is usually well tolerated but can cause gastrointestinal discomfort. There is at least
one reported case of rhabdomyolysis in association with concomitant use of atorvastatin and
gemfibrozil (Duell et al. 1998).
Atorvastatin 40 mg twice daily was found not to affect the oxidative metabolism of antipyrine
(Yang et al. 1996). Coadministration with atorvastatin 80 mg/day resulted in a 8% decrease and
35% increase in the Cmax and AUC of terfenadine, respectively, compared with values after
ingestion of terfenadine alone (Stern et al. 1998a). A 10-day administration of atorvastatin 80
mg/day increased the Cmax and AUC of digoxin 20% and 15% (Boyd et al. 2000). During
coadministration of atorvastatin 10 mg once daily with cimetidine 300 mg four times daily for
2 weeks, the AUC of atorvastatin (measured by REA) remained unchanged (Stern et al. 1998b).
The Cmax and AUC of atorvastatin, measured as HMG-CoA reductase inhibitors, were
increased 38% and 33%, respectively, by erythromycin 500 mg 4 times daily for 7 days (Siedlik
et al. 1999). A 4-day pretreatment with itraconazole 200 mg/day increased the AUC of
atorvastatin acid and of atorvastatin lactone about 3- and 4-fold, respectively. Furthermore, the
mean AUC of 2-hydroxyatorvastatin and of 2-hydroxyatorvastatin lactone was decreased by
43% and 62% by itraconazole (Kantola et al. 1998c).
3.5. Pravastatin
Pravastatin is a hydrophilic HMG-CoA reductase inhibitor administered in its active open acid
form. Following oral ingestion, it is absorbed rapidly, and Cmax is reached at approximately one
hour (Pan 1991). After oral administration, about 34% of the dose is absorbed. The absolute
bioavailability of pravastatin averages 18%, indicating that about 50% of the ingested dose
undergoes presystemic metabolism (Singhvi et al. 1990). The Cmax and AUC values of
pravastatin are dose-proportional (Pan et al. 1990a). In hypercholesterolemic patients, its
bioavailability is reduced by about 30% when it is taken with food (Pan et al. 1993).
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Approximately 50% of the circulating pravastatin is bound to plasma proteins. Its volume of
distribution in steady-state conditions and during the elimination phase averages 0.46 and 0.88
l/kg (Singhvi et al. 1990). Total and renal clearance values average 13.5 and 6.5 ml/min/kg,
respectively. Its elimination t½ is about 2 hours (Pan 1991). After i.v. administration of
radiolabeled pravastatin, 60% was recovered in urine and 34% in feces, indicating substantial
biliary excretion (Singhvi et al. 1990). Following oral ingestion, recovery of radioactivity was
20% in urine and 71% in feces (Singhvi et al. 1990).
Pravastatin is extensively metabolized during the first pass and has a hepatic extraction ratio of
0.66 (Pan et al. 1991). It has two major metabolites, the 3α-hydroxy isomeric metabolite and
3α,5β,6β-trihydroxy isomeric metabolite (Everett et al. 1991). The former of these possesses
1/40 of the pharmacologic activity of the parent drug, whereas the latter is considered inactive.
At least 15 other metabolites have been identified in urine, feces, and plasma (Everett et al.
1991). Pravastatin accounts for about 75% of the serum AUC for HMG-CoA reductase
inhibitory activity (Pan et al. 1990b). In vitro, its biotransformation is partly inhibited by
CYP3A4 inhibitors; some other CYP enzymes appear also to play a role in its metabolism
(Jacobsen et al. 1999).
As with other HMG-CoA reductase inhibitors, gastrointestinal complaints are the most
common adverse effects related to therapy with pravastatin. In a 2.5-year follow-up study in
heart-transplant patients, pravastatin was discontinued in a few cases due to myopathy after its
coadministration with cyclosporine (Park et al. 1998).
In renal-transplant patients receiving cyclosporine, considerably elevated values have been
found for Cmax and AUC (Regazzi et al. 1994; Olbricht et al. 1997). In a study by Pan et al.
(1991), propranolol reduced the mean AUC value of total inhibitors by 23% and that of
pravastatin by 16%. Digoxin did not significantly alter steady-state pharmacokinetics of
pravastatin (Triscari et al. 1993). A 7-day treatment with erythromycin 500 mg 4 times daily
increased the Cmax and AUC of pravastatin 2.2-fold and 1.7-fold (Donahue et al. 1998). A 4-
day administration of itraconazole 200 mg once daily resulted in a slight but statistically
nonsignificant increase in the AUC of pravastatin and a 1.7-fold increased AUC value for total
inhibitors (Neuvonen et al. 1998). A 2-week pretreatment with diltiazem 120 mg twice daily
did not affect the Cmax or AUC of pravastatin (Azie et al. 1998).
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3.6. Triazolam
Triazolam, structurally a triazolobenzodiazepine and closely related to alprazolam and
midazolam, is a short-acting benzodiazepine hypnotic. It binds to benzodiazepine receptors and
enhances GABAergic synaptic inhibition in the central nervous system. After oral
administration, about 85% of a triazolam dose is absorbed. Its tmax is from 1 to 2 hours. It has
an oral bioavailability of 50 to 60%, indicating that it is subject to first-pass metabolism. It is
about 90% bound to plasma proteins. Triazolam has an apparent volume of distribution of 1.1
l/kg. Its elimination t½ ranges from 2 to 4 hours (Eberts et al. 1981).
Triazolam is extensively metabolized and has two major metabolites, α-hydroxy- and 4-
hydroxytriazolam (Eberts et al. 1981). Of these, α-hydroxytriazolam, but not 4-
hydroxytriazolam, shows pharmacological activity (Ziegler et al. 1983). Triazolam is primarily
biotransformed by CYP3A4 (Kronbach et al. 1989; von Moltke et al. 1996), and its metabolites
are subsequently glucuronized, with about 90% of the dose excreted renally. Apparent oral
clearance of triazolam has been shown to be significantly reduced in elderly as compared with
young subjects (Greenblatt et al. 1983). The pharmacokinetics of triazolam have not been
found to differ between patients with hepatic cirrhosis and healthy volunteers (Robin et al.
1993). Its elimination was unaffected by renal disease (Kroboth et al. 1985).
Like other benzodiazepines, triazolam exhibits hypnotic, muscle relaxant, and anticonvulsant
effects in animals; in humans it shortens the time to onset of sleep, increases total sleep
duration, and decreases the frequency of nocturnal awakening. Large doses of triazolam can
cause ventilatory suppression. It impairs cognitive and psychomotor functions like driving
skills (Pakes et al. 1981). Its main adverse effects include amnesic episodes, rebound anxiety,
and aggression (Dollery 1999).
Triazolam has been shown to be very susceptible to interactions with CYP3A4 inhibitors.
Erythromycin pretreatment 333 mg t.i.d. for three days doubled triazolam AUC (Phillips et al.
1986). The azole antifungals itraconazole and ketoconazole increased the AUC of triazolam
27-fold and 22-fold and prolonged triazolam t½ 7-fold and 6-fold, respectively (Varhe et al.
1994), markedly increasing the intensity and duration of triazolam effects. Its AUC was
increased by fluconazole but not by terbinafine (Varhe et al. 1996a). The calcium-channel
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antagonist diltiazem also increased triazolam concentrations (Varhe et al. 1996b; Kosuge et al.
1997). A single dose of grapefruit juice increased its AUC by about 50% and slightly increased
its effects (Hukkinen et al. 1995).
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AIMS OF THE STUDY
The overall aim of this study was to discover the potential of grapefruit juice to affect the
pharmacokinetics of drugs metabolized to varying degree during their first-pass and elimination
phases by CYP3A4 and to characterize factors that determine grapefruit juice-drug interaction.
More specific aims of this study were:
To study the possible effects of multiple-dose grapefruit juice on the pharmacokinetics of
buspirone, cisapride, simvastatin, atorvastatin, pravastatin, and triazolam (Studies I-V).
To investigate the effect of differing doses of grapefruit juice on the extent of interaction, with
triazolam serving as a model of a CYP3A4 substrate (Study V).
To study the duration of effect of grapefruit juice on the pharmacokinetics of CYP3A4




After receiving adequate written and oral information on the study protocols, all volunteers
gave their written consent before entering the study. All studies were conducted according to
the Declaration of Helsinki. The study protocols were approved by the Ethics Committee of the
Department of Clinical Pharmacology, University of Helsinki. The Finnish National Agency
for Medicines was informed about the studies.
Each study included 10 to 12 healthy volunteers (age range, 19 to 34 years; weight range, 50 to
101 kg); in total, 62 subjects (35 males, 27 females) participated. Ten subjects participated in
more than one study: seven subjects two times, two subjects three times, and one subject four
times. None was a regular smoker. The volunteers used no continuous medication except for 12
female subjects taking oral contraceptive steroids. All were considered to be healthy according
to medical history, clinical examination, and routine laboratory tests (e.g., blood hemoglobin,
serum alanine aminotransferase, creatinine, and creatine kinase). In addition, in Study II, a 12-
lead electrocardiogram was taken before and during the study. None of the female subjects was
pregnant or nursing, and they were instructed to avoid becoming pregnant during the study.
Excessive alcohol consumption was an exclusion criterion. Subjects who had taken any kind of
medication relevant to the study during the 4 weeks prior to the study, who had donated blood,




All the study drugs were in current clinical use in Finland, and only oral formulations were
used. Studies I, II, III, and IV were randomized, cross-over studies with two phases (one of
which served as a control). Study IV comprised two different studies (a and b). The phases
were separated by a 2-week washout period (3 weeks in Study IV). Study V was a randomized,
cross-over study with four phases (one control phase) and washout periods of 2 weeks. Study
VI was a nonrandomized cross-over study with five phases. Following ingestion of the drug,
timed blood samples were taken for up 12 to 72 hours for the determination of the plasma or
serum drug concentrations. Study designs are summarized below and in Table 1.
In each study, the volunteers ate a standard meal 3 to 4 hours following the administration of
the drug and then a standard light meal 7 to 8 hours afterwards. Use of alcohol or, coffee and
cola drinks or smoking during the study days was not allowed. Consumption of grapefruit
products was forbidden during the pretreatment periods and study days except for intake
according to the protocol. The same grapefruit juice brand was used in every study, Minute
Maid frozen concentrated grapefruit juice (12 ounces [355 ml]), from Coca Cola Foods,
Houston, Texas, USA. Before administration, the grapefruit juice was made at double strength
with tap water in Studies I to VI (50/50, vol/vol). In addition, also normal-strength grapefruit
juice was used in Study V (25/75, vol/vol).
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Study drug Administration of
study drug
day             hours
I GFJ (double strength) 200 ml t.i.d
for 2 days (at 7.00-8.00, 12.00-
13.00, and 20.00-21.00) plus on
day 3 (at 9.00, 9.30, and 10.30)
Water
2 Buspirone 10 mg  3                9.00-9.30
II As in Study I 2 Cisapride 10 mg 3                 9.00-9.30
III As in Study I 2 Simvastatin 60 mg 3                 9.00-9.30
IVa
IVb
As in Study I





3                 9.00-9.30
3                 9.00-9.30
V Water
GFJ 200 ml (normal strength)
GFJ 200 ml (double strength)
GFJ as in Study I
2 Triazolam 0.25 mg 1                 9.00-9.30
1                 9.00-9.30
1                 9.00-9.30
3                 9.00-9.30
VI Water
GFJ as in Study I
GFJ as in Study I
GFJ as in Study I
GFJ as in Study I
See text Simvastatin 40 mg 1                 9.00-9.30
3                 9.00-9.30
6                 9.00-9.30
4                 9.00-9.30
10               9.00-9.30
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Study I
Ten volunteers (4 males, 6 females, 2 OC-users) participated in a randomized cross-over study
with  two phases separated by a 2-week washout period. Pretreatments were double-strength
grapefruit juice or water 200 ml t.i.d. for 2 days. On the third day, a single 10-mg dose of
buspirone (Buspar, Bristol-Myers Squibb, Espoo, Finland) was ingested at 9 a.m. with 200 ml
double-strength grapefruit juice or water. In addition, 200 ml grapefruit juice or water was
ingested ½ and 1½ hours after the drug. Blood samples were obtained for 12 hours after
administration for determination of plasma concentrations of buspirone. Psychomotor tests
were performed for 8 hours to measure the effects of buspirone.
Study II
Ten healthy volunteers (all males) participated in this randomized cross-over study with a 2-
week washout period. Pretreatments were identical to those in Study I. On the third day, the
subjects were given 10 mg cisapride (one 10-mg Prepulsid tablet, Janssen-Cilag, Beerse,
Belgium) at 9 a.m. with double-strength grapefruit juice or water 200 ml. In addition, 200 ml
grapefruit juice or water was ingested ½ and 1½ hours after the drug. Blood samples were
drawn for up to 36 hours after the drug for determination of plasma concentrations of cisapride.
In addition, 12-lead ECGs were taken before and 2, 5, 8, and 12 hours after the drug.
Study III
Ten volunteers (5 males, 5 females, 3 OC-users) participated in a randomized cross-over study
with two phases, separated by a 2-week washout period. Pretreatments were identical to those
in Study I. On the third day, the volunteers received simvastatin 60 mg (3 Zocor 20 mg tablets,
Merck Sharp & Dohme BV, Haarlem, The Netherlands) at 9 a.m. with double-strength
grapefruit juice or water 200 ml. In addition, 200 ml grapefruit juice or water was ingested ½
and 1½ hours after the drug. Blood samples were drawn as in Study I - except that blood was
not sampled at 1½ hours - for determination of serum concentrations of simvastatin,
simvastatin acid, and HMG-CoA reductase inhibitors.
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Study IV
This study included two separate investigations, IVa and IVb. Study design and pretreatments
were in both investigations as in previous studies. A 3-week washout period was used. In Study
IVa, 12 healthy volunteers (6 males and 6 females, 4 OC-users) received on the third day 40 mg
atorvastatin (two 20-mg Lipitor tablets, Warner Lambert Nordic AB, Solna, Sweden) at 9 a.m.
with double-strength grapefruit juice or water 200 ml. In addition, 200 ml grapefruit juice or
water was ingested ½ and 1½ hours after the drug. After the third day, the subjects continued to
drink double-strength grapefruit juice or water 200 ml t.i.d. for 2 more  days. Blood samples
were obtained for 72 hours after the drug administration for determination of serum
concentrations of atorvastatin acid, its metabolites, and HMG-CoA reductase inhibitors. In
Study IVb, the volunteers (3 males and 8 females, 1 OC-user) received 40 mg pravastatin (two
20-mg Pravachol tablets, Bristol-Myers Squibb, Bromma, Sweden) at 9 a.m. with double-
strength grapefruit juice or water 200 ml. In addition, 200 ml grapefruit juice or water was
ingested ½ and 1½ hours after the drug. Blood samples were obtained for 24 hours after the
drug for determination of serum concentrations of pravastatin, pravastatin lactone, and HMG-
CoA reductase inhibitors.
Study V
Twelve subjects (6 males, 6 females, 3 OC-users) participated in this randomized cross-over
study that consisted of four phases with 2-week washout periods. Volunteers received 0.25 mg
triazolam (Halcion, Upjohn, Kalamazoo, MI, USA) with 200 ml water, 200 ml normal-strength
or double-strength grapefruit juice, or on the third day of repeated (t.i.d.) administration of
double-strength grapefruit juice (as in previous studies). Blood samples were collected for 23
hours after the drug for determination of plasma concentrations of triazolam, and the effects of
triazolam were measured by four psychomotor tests for up to 10 hours.
Study VI
This cross-over study consisted of three parts and 5 study days, during each study day 10
healthy volunteers (9 males and 1 female) received 40 mg simvastatin (two Zocor 20 mg
tablets, Merck Sharp & Dohme BV, Haarlem, The Netherlands). The three parts of the study
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were separated by an interval of 2 weeks to allow simvastatin-free days between the study days.
In the first part of the study, each volunteer was administered 40 mg simvastatin at 9 a.m. with
200 ml water. In the second study part, volunteers received juice as pre-treatment exactly as in
Study I. On day 3, each subject was given 40 mg simvastatin at 9 a.m. with 200 ml grapefruit
juice. In addition, the subjects ingested juice ½ and 1½ hours after simvastatin intake. Three
days after the last dose of grapefruit juice, 40 mg simvastatin was given with water at 9 a.m. In
the third study part, the subjects ingested grapefruit juice t.i.d. for 3 days as in the second part
of the study. Twenty-four hours after the last dose of grapefruit juice, each subject received 40
mg simvastatin with water at 9 a.m. Seven days after the last dose of grapefruit juice, each
subject was given 40 mg simvastatin water at 9 a.m. Blood samples were collected for 12 hours
after the drug for determination of serum concentrations of simvastatin and simvastatin acid.
3. Blood sampling
On the day of administration of the study drug, a forearm vein was cannulated with a plastic
cannula and kept patent with an obturator. Timed blood samples were drawn before
administration of buspirone and ½, 1, 1½, 2, 3, 4, 5, 6, 8, 10, and 12 hours afterwards in Study
I. In Study II, blood samples were obtained before administration of cisapride and ½, 1, 1½, 2,
3, 4, 5, 6, 9, 12, 24, and 32 hours afterwards. In Study III, the blood samples were collected
before administration of simvastatin and at ½, 1, 2, 3, 4, 5, 6, 8, 10, and 12 hours. In Studies
IVa and IVb, the time-points for blood sampling were before and ½, 1, 2, 3, 4, 6, 8, 10, 12, 24,
36, 48, and 72 hours after administration of atorvastatin, and before and ½, 1, 2, 3, 4, 6, 8, 10,
12, and 24 hours after administration of pravastatin. In Study V, blood samples were obtained
before administration of triazolam and at ½, 1, 1½, 2, 3, 4, 5, 6, 8, 10, and 23 hours. In Study
VI, the blood samples were drawn before and 1, 2, 3, 4, 6, 8, 10, and 12 hours after
administration of simvastatin. The blood samples were drawn into tubes containing
ethylenediaminetetra-acetic acid (EDTA) in Studies I, II, and V and into siliconized Venoject
tubes in Studies III, IV, and VI. Plasma or serum was separated within 30 minutes after blood
sampling and stored at -70°C.
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4. Determination of drug concentrations
Buspirone (Study I). Plasma buspirone concentrations were measured by means of a gas
chromatographic method that involved solid-phase extraction and nitrogen-phosphorus
detection (Gaillard et al. 1993; Kivistö et al. 1999). Zolpidem served as an internal standard.
The limit of quantification was 0.20 ng/ml. The between-day coefficient of variation (CV) was
< 11%.
Cisapride (Study II). Plasma concentrations of cisapride were determined by use of reversed-
phase high-performance liquid chromatography (HPLC) that involved solid phase extraction
(Woestenborghs et al. 1988) and fluorescence detection (Preechagoon and Charles 1995).
Metoclopramide served as an internal standard. The quantification limit for cisapride was 2.0
ng/ml. The between-day CV was < 13%.
Simvastatin, simvastatin acid, and active and total HMG-CoA reductase inhibitors (Study
III). Serum concentrations of simvastatin and simvastatin acid were measured by turbo
ionspray liquid chromatography-tandem mass spectrometry (LC-MS-MS) in the positive ion
mode as described in the original paper (Study III). The limit of quantification was 0.5 ng/ml
for simvastatin and simvastatin acid and the interassay CV < 8%.
In Studies III and IV, the serum concentrations of statins and their metabolites were determined
by means of a nonspecific radioenzyme inhibition assay (REA) in addition to a specific method
(LC-MS-MS). In REA, serum samples were assayed for inherent (active) HMG-CoA reductase
inhibitory activity resulting from the β-hydroxyacid form of the parent drug and active
metabolites, and after base hydrolysis which converts inactive lactones to active species (total
inhibitory activity). This method is considered to be nonspecific because it quantitates the
inhibitory activity against HMG-CoA reductase activity rather than actual concentrations of a
drug or its metabolite(s).
Serum concentrations of active and total HMG-CoA reductase inhibitors were measured in
Study III as described by Manning et al. (1989). Base hydrolysis was achieved by incubation of
0.1 ml serum with 0.01 N potassium hydroxide. Concentrations were reported as nanogram
equivalents (ng-eq) of simvastatin acid per milliliter. The limits of quantification for active and
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total HMG-CoA reductase inhibitors were 1.0 ng-eq/ml and 2.0 ng-eq/ml. For active HMG-
CoA reductase inhibitors, the interassay CV was < 12 %. For total HMG-CoA reductase
inhibitors, the interassay CV was 5% or less.
Atorvastatin acid, its metabolites, pravastatin, pravastatin lactone, and active and total
HMG-CoA reductase inhibitors (Study IV). Atorvastatin and its metabolites were quantified
by LC-MS-MS, as described in the original paper (Study IVa). The limit of quantification was
0.5 ng/ml for all analytes. The interassay CV was < 10% for all analytes at relevant
concentrations.
In Study IVb, serum concentrations of pravastatin and pravastatin lactone were determined by
liquid chromatography with electronspray tandem mass spectrometry in the positive ion mode
(LC-MS-MS). The limit of quantification was 0.5 ng/ml for pravastatin and its lactone. The CV
was ≤ 8% for both analytes at relevant concentrations.
Serum concentrations of active (no hydrolysis) and total (after hydrolysis of lactones) HMG-
CoA reductase inhibitors were determined with the use of REA (Manning et al. 1989).
Concentrations were reported as nanogram-equivalents (ng-eq) of atorvastatin acid per
milliliter (Study IVa) and as nanogram-equivalents (ng-eq) of pravastatin sodium per milliliter
(Study IVb). The quantification limit for active and total HMG-CoA reductase inhibitors was
0.5 and 1.0 ng-eq/ml, in Study IVa. In Study IVb, the quantification limit for active and total
HMG-CoA reductase inhibitors was 2.0 and 5.0 ng-eq/ml. The CV was < 10% for all analytes
at relevant concentrations.
Triazolam (Study V). Plasma triazolam concentrations were determined by use of capillary
gas chromatography (Gaillard et al. 1993). This method involved solid phase extraction and
electron-capture detection. The limit of quantification was 0.1 ng/ml. The between-day CV was
< 16%.
Simvastatin and simvastatin acid (Study VI). Serum concentrations of simvastatin and
simvastatin acid were assayed by use of turbo ionspray LC-MS-MS in the positive ion mode as
described in the original paper (Study III). The quantification limit was 0.1 ng/ml for both
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simvastatin and simvastatin acid. The between-day CV for simvastatin acid was < 12%. The
between-day CV for simvastatin was   < 15%.
5. Pharmacokinetic calculations
The pharmacokinetics of the study drugs were characterized by the following variables: the
peak concentration in plasma or serum (Cmax), time of peak concentration (tmax), the elimination
half-life (t½), and areas under the plasma or serum concentration-time curve [AUC(0-t) and
AUC(0-∞)]. The Cmax and tmax values were obtained directly from the original data. The
terminal log-linear phase of the plasma or serum drug concentration-time curve was identified
visually for each subject. The elimination coefficient (kel) was determined from the log-linear
phase of the drug concentration-time curve by linear regression analysis. The t½ was calculated
by the equation: t½ = ln2/kel. The AUC(0-t) values were calculated by use of the trapezoidal
rule. The AUC(0-∞) was obtained by adding to the AUC(0-t) the residual area AUC(t-∞)
calculated as the last measurable concentration divided by the kel. Pharmacokinetic calculations
were performed with the pharmacokinetic program MK-Model, version 5.0 (Biosoft,
Cambridge, UK) in all studies, except for Study III, in which the Top Fit version 2.0 program
(Dr. Karl Thomae GmbH, Schering AG, Gödecke AG, Germany) was used.
6. Pharmacodynamic testing
The effects of buspirone and triazolam were tested in Studies I and V, respectively. Six
different tests were used in Study I: subjective drug effect, subjective drowsiness, DSST,
CFFT, and postural sway with eyes open and eyes closed. In Study V, the same tests were used
as in Study I except for postural sway. Pharmacodynamic measurements were performed after
each blood sampling for up to 8 hours in Study I and up to 10 hours in Study V. The volunteers
were trained to perform the psychomotor tests properly before the commencement of each trial.
Subjective drug effect. Subjective drug effect was evaluated on a 100 mm-long horizontal
visual analogue scale (VAS) with adjectives with opposite meanings at both ends. The subject
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puts a mark somewhere on this scale as a self-rating of his or her feelings at the moment. In this
test, the scale ranges from No drug effect to Maximal drug effect, expressed in Finnish.
Subjective drowsiness. The performance of this test is identical to that of the subjective drug
effect, except that Alert and Drowsy are at the ends of the scale for self-evaluation of subjective
drowsiness.
DSST. The Digit Symbol Substitution Test has been demonstrated to be sensitive for
measuring both cognitive and motor effects of psychoactive drugs (Stone 1984). In this test, the
volunteer substitutes digits (1-9) for simple coded symbols. The number of correctly substituted
digits in 3 minutes was the test result in Study I. In Study V, the recording time was 2 minutes.
To prevent subjects’ learning the code, the symbols corresponding to the digits were different
at the each time of recording.
CFFT. The results of this test are affected by the sensitivity of the visual cortex, the state of
arousal of the CNS, and the integrative activity of the CNS (Smith and Misiak 1976). In this
test, discrimination of the fusion of a flickering red light is measured. For the first
measurement, the frequency of flickering constantly increases, and the subject indicates the
point at which the flickering lights give the sensation of a steady light. This threshold frequency
expressed in Hertz is the result of the measurement. After this, another measurement is
performed during which lights flicker at a decreasing frequency, and the subject indicates the
point at which flickering is distinguishable. The mean of these two measurements is the result
of the test. The distance from the eyes of the volunteer to the flickering lights is standardized to
1 m. To control variations in pupillary diameter, special spectacles are worn, and illumination
is kept constant during each study day. It has been shown that hypnotics like benzodiazepines
reduce the test score and stimulants such as amphetamine increase it (Smith and Misiak 1976;
Longbottom and Pleuvry 1984).
Postural sway. In this test, postural sway of the subject standing on a metal plate is recorded
by means of a computer-controlled swaymeter (Erikois-Elektroniikka Ltd., Orimattila,
Finland). The recorded parameter is the speed of the subject’s mass center (mm/min). The
measurement time is 30 seconds with the subject’s eyes open and thereafter 30 seconds with
the eyes closed. Body sway is an indicator of corrective mechanisms to maintain an upright
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posture (Robin et al. 1991). The precision at which the automatic equilibration system of a
subject maintains the center of gravity close to the mid-position depends on the subject’s state
of arousal (Patat and Foulhoux 1985). Benzodiazepines have been shown to increase body
sway (Backman et al. 1996), whereas buspirone has had negligible effects (Lamberg et al.
1998a).
The incremental (body sway, VAS) or decremental (DSST, CFFT) area under the effect-
against-time curve (i.e., areas above or below baseline) was calculated by the linear trapezoidal
rule from 0 to 4 hours and from 0 to 8 hours in Study I and from 0 to 6 hours in Study V.
ECG recording
In Study II, 12-lead ECG recordings were taken before the administration of cisapride and 2, 5,
8, and 12 hours later. Heart rate and ECG intervals (PQ, QRS, and QT) were measured with
automated software (Cardiovit AT-6, Schiller, Switzerland). The QT interval was corrected for
heart rate by dividing the measured QT interval by the square root of the RR interval (QTc
interval).
7. Statistical analysis
Data are expressed as mean values ± SEM (Studies I and III), mean values ± SD (Studies II, IV-
VI), or median with range in the case of tmax. Results are presented in the figures as mean
values ± SEM. Pharmacokinetic variables were log-transformed before analysis when
appropriate. In Studies I to IV, continuous pharmacokinetic variables (Cmax, t½, AUC),
pharmacodynamic variables (AUC values in Study I), and QTc data (Study II) between the
phases were compared with use of the Student t-test (two-tailed). The tmax values were
compared with the Wilcoxon signed rank test. In Studies V and VI, the pharmacokinetic
variables and the AUC values for pharmacodynamic tests (Study V) between the phases were
compared with use of analysis of variance (ANOVA); a posteriori testing was done by the
Tukey test. The tmax values were compared with Friedman’s two-way ANOVA, followed by the
Wilcoxon test. Pearson’s linear correlation coefficient was used to test linear correlations in
Study II. In all studies, p < 0.05 was considered to be statistically significant. The statistical
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analyses were performed with the statistical program Systat, version 5.0 (Systat, Evanston, IN,
USA) in Studies I to IV, and version 6.0.1 (SPSS, Chicago, IL, USA) in Studies V and VI.
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RESULTS
1. Effects of grapefruit juice on the pharmacokinetics of buspirone (Study I)
Grapefruit juice had a considerable effect on plasma concentrations of buspirone (Table 2, Figs.
1 and 2). The mean Cmax of buspirone was increased by grapefruit juice about 4-fold (p < 0.01),
and its mean AUC(0-∞) was affected even more, a mean 9-fold (range, 3-fold to 20-fold; p <
0.01). The tmax of buspirone occurred significantly later in the grapefruit juice than in the water
phase (3 hours versus 0.75 hour; p < 0.01). Its t½ was 1.8 hours in the water phase and 2.7
hours in the grapefruit juice phase (p < 0.01).
The results of the pharmacodynamic tests were only modestly affected by grapefruit juice
ingestion. The subjective overall drug effect was significantly (p < 0.01) increased, but no other
differences appeared between the grapefruit juice and the water phase in the psychomotor tests.
Mild side-effects were reported by 8 subjects during the grapefruit juice and 7 subjects during
the water phase. These side-effects resolved spontaneously within 1 to 3 hours in all cases.
2. Effects of grapefruit juice on the pharmacokinetics of cisapride (Study II)
Grapefruit juice considerably increased cisapride concentrations (Table 2, Figs. 1 and 2). The
mean Cmax and AUC(0-∞) of cisapride were increased by 81% and 144% (p < 0.01). The tmax of
cisapride occurred significantly later in the grapefruit juice than in the water phase (2.5 hours
versus 1.5 hours; p < 0.05). Grapefruit juice increased the elimination t½ of cisapride by about
24% (p < 0.05).
The mean QTc interval at 5 hours was slightly higher than the baseline value during both study
phases (p < 0.01), with no significant difference in QTc interval found between the phases at
any time-point.
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3. Effects of grapefruit juice on the pharmacokinetics of simvastatin (Study III)
Grapefruit juice caused great changes in the pharmacokinetics of simvastatin and its active
form, simvastatin acid (Table 2, Figs. 1 and 2). The mean Cmax and AUC(0-∞) values of
simvastatin were increased approximately 9-fold (p < 0.01) and 16-fold (p < 0.05). During this
phase, the tmax of simvastatin was nonsignificantly delayed compared with the water phase (p =
0.065). The t½ of simvastatin was not changed by grapefruit juice. The ratio of the Cmax of
simvastatin in the grapefruit juice to that of the water phase ranged from 5.1 to 31.4; the
corresponding ratio for the AUC(0-∞) ranged from 9.0 to 37.7. The Cmax and AUC(0-∞) of
simvastatin acid were increased about 7-fold (p < 0.01) by grapefruit juice, but the tmax and t½
of simvastatin acid remained unaltered.
The mean AUC(0-∞) of active and total HMG-CoA reductase inhibitors were increased 2.4-
and 3.6-fold (p < 0.01) by grapefruit juice. The individual changes ranged from 1.0- to 4.1-fold
for the AUC(0-∞) of active inhibitors and from 2.2 to 7.7-fold for the AUC(0-∞) of total
inhibitors.
4. Effects of grapefruit juice on the pharmacokinetics of atorvastatin and pravastatin
(Study IV)
Multiple-dose grapefruit juice (ingested on a total of 5 consecutive days) significantly elevated
serum concentrations of atorvastatin acid and atorvastatin lactone and reduced formation of 2-
hydroxyatorvastatin (Table 2, Figs. 1 and 2). The Cmax of atorvastatin acid remained
unchanged, whereas the AUC(0-72) was increased about 2.5-fold (p < 0.01) by grapefruit juice,
with individual increases ranging from 1.7- to 5.7-fold. The median tmax of atorvastatin acid
was prolonged from 1 hour to 3 hours (p < 0.01). The elimination t½ of atorvastatin acid
increased from 7.8 hours in the water to 13.3 hours in the grapefruit-juice phase (p < 0.01).
Grapefruit juice increased the mean Cmax and AUC(0-72) of atorvastatin lactone 2.6-fold and
3.3-fold (p < 0.01). The median tmax of atorvastatin lactone was prolonged from 3 to 4 hours (p
< 0.05), and the mean elimination t½ from 8.3 to 12.6 hours (p < 0.05) by grapefruit juice.
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After grapefruit juice ingestion, the mean Cmax and AUC(0-72) of 2-hydroxyatorvastatin acid
were 25% (p < 0.001) and 58% (p < 0.001), of corresponding values in the water phase. The
median tmax of 2-hydroxyatorvastatin acid was prolonged from 1.5 to 10 hours (p < 0.01), and
the mean elimination t½  from 9.7 to 17.7 hours (p < 0.001) by grapefruit juice. Grapefruit juice
decreased the mean Cmax and AUC(0-72) of 2-hydroxyatorvastatin lactone to 44% (p < 0.001)
and 80% (p < 0.05), of the corresponding values in the water phase. The median tmax was
increased from 3.5 to 10 hours (p < 0.01) and the mean elimination t½ from 10.3 to 15.0 hours
(p < 0.05).
During the grapefruit-juice phase, the mean AUC(0-72) of active and total HMG-CoA
reductase inhibitors were 28% (p < 0.05) and 50% (p < 0.01) greater than in the water phase.
The mean elimination t½ of total HMG-CoA reductase inhibitors averaged 13.4 hours with
water and 17.0 hours with grapefruit juice (p < 0.01).
Grapefruit juice showed no significant effects on the pharmacokinetics of pravastatin, with the
AUC(0-24), Cmax, tmax, and elimination t½ remaining unchanged (Table 2, Figs. 1 and 2). In
addition, grapefruit juice did not alter the AUC(0-24), Cmax, or tmax of pravastatin lactone; the
elimination t½ of pravastatin lactone could not be calculated because of low serum
concentrations. Grapefruit juice did not significantly affect the AUC(0-24), Cmax, or t½ of active
or total HMG-CoA reductase inhibitors. The median tmax of total HMG-CoA reductase
inhibitors remained unaltered, whereas that of active HMG-CoA reductase inhibitors was
increased from 1 to 2 hours (p < 0.05).
5. Effect of grapefruit juice dose on the interaction between grapefruit juice and
triazolam (Study V)
The AUC(0-∞) of triazolam was increased by 53% (p < 0.01), 49% (p < 0.0l), and 143% (p <
0.001) by a single dose of normal-strength, by a single dose of double-strength, and by
multiple-dose double-strength grapefruit juice, respectively (Table 2, Fig. 1). The Cmax of
triazolam was increased by 40% by a single dose of normal-strength grapefruit juice (p < 0.01)
and multiple-dose grapefruit juice (p < 0.01) and by 25% by a single dose of double-strength
grapefruit juice (p < 0.05; Table 2, Fig. 2). The increase in the AUC(0-∞) of triazolam was
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significantly (p < 0.001) greater after repeated consumption of grapefruit juice than after a
single dose of normal- or double-strength grapefruit juice. Multiple-dose administration of
grapefruit juice increased the t½ of triazolam by 54% (p < 0.001), whereas it was not
significantly changed by a single dose of either normal- or double-strength juice.
The effects of triazolam were significantly (p < 0.05) increased by multiple-dose administration
of grapefruit juice according to the DSST and based on VAS tests for overall drug effect, and
drowsiness.
Figure 1. Mean AUC values of study drugs after ingestion of grapefruit juice 200 ml t.i.d. for 3
days, expressed as percentages of corresponding values during the water phase (control). Simva
= simvastatin; Buspi = buspirone; Cisa = cisapride; Atorva = atorvastatin; Triaz = triazolam;
Prava = pravastatin.
































6. Duration of effect of grapefruit juice on the pharmacokinetics of simvastatin (Study
VI)
Concomitant administration with grapefruit juice increased the mean Cmax and AUC(0-∞) of
simvastatin 12.0-fold (p < 0.001) and 13.5-fold (p < 0.001), compared with the water phase.
When simvastatin was ingested 24 hours after the last dose of grapefruit juice, Cmax and
AUC(0-∞) were increased 2.4-fold (p < 0.01) and 2.1-fold (p < 0.001) compared with the water
phase. When simvastatin was administered 3 days after the final dose of grapefruit juice, the
Cmax and and AUC(0-∞) were increased 1.5-fold (p = 0.12) and 1.4-fold (p = 0.09),
respectively. Seven days after cessation of intake of grapefruit juice, no differences appeared in
the Cmax and AUC(0-∞) between the phases. When simvastatin was administered 24 hours or 3
days after cessation of intake of grapefruit juice, the mean oral clearance (Cloral) of simvastatin
was 50% (p < 0.001) and 63% (p = 0.09) of that during the water phase.
Concomitant administration of simvastatin with grapefruit juice increased the mean Cmax and
AUC(0-∞) of simvastatin acid 5.0- and 4.5-fold, compared with the water phase (p < 0.001).
When simvastatin was taken 24 hours after the last dose of grapefruit juice, the Cmax and
AUC(0-∞) of simvastatin acid were increased 1.7-fold (p < 0.01). After an interval of 3 or 7
days between ingestion of grapefruit juice and simvastatin, the pharmacokinetic variables of
simvastatin acid did not differ significantly from those in the water phase.
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Figure 2. Mean Cmax values of study drugs after ingestion of grapefruit juice 200 ml t.i.d. for 3
days, expressed as percentages of corresponding values during the water phase (control). Simva
= simvastatin; Buspi = buspirone; Cisa = cisapride; Atorva = atorvastatin; Triaz = triazolam;
Prava = pravastatin.


























Table 2. Summary of effects of ingestion of grapefruit juice 200 ml t.i.d. for 3 days on selected
pharmacokinetic parameters of study drugs.
    Study drug AUC Cmax tmax t½
      buspirone ↑↑↑ ↑↑↑ ↑↑ ↑
      simvastatin ↑↑↑ ↑↑↑ ↔ ↔
      cisapride ↑↑ ↑ ↑ ↑
      atorvastatin ↑↑ ↔ ↑↑ ↑
      pravastatin ↔ ↔ ↔ ↔
      triazolam ↑↑ ↑ ↔ ↑
Changes (increase or decrease) indicated as follows:
↑/↓    15 to 100% change (p < 0.05)
↑↑/↓↓    101 to 300% change (p < 0.05)
↑↑↑/↓↓↓    change > 300% (p < 0.05)




All of the subjects participating in the present series of investigations were young and healthy.
Cardiac, hepatic, and renal diseases may modify drug metabolism and excretion and therefore
have a substantial effect on drug pharmacokinetics. Thus, results of these studies may not be
directly extrapolated to subgroups with illnesses or who use concomitant medications. Every
study was of cross-over design. In this design, each subject serves as his or her own control so
that the large interindividual variation often associated with pharmacokinetic interaction studies
can be minimized. The randomization and balancing used in most of the studies, together with
adequately long wash-out periods, helped to avoid any possible carry-over effect. Based on the
elimination half-lives of study drugs and the estimated duration of the grapefruit-juice effect, it
was regarded that a 2- to 3-week washout period is sufficiently lengthy.
The number of subjects in these investigations was relatively small. However, based on
previous interaction studies and information on pharmacokinetic properties of the study drugs,
it was considered that, if in a sample with size of 10 to 12 volunteers a 30 to 50% difference in
AUC is not statistically significant, then the probability of clinically important interaction is
small. In each of the six studies, grapefruit juice was used (at least in one phase) according to
one and the same scheme, to allow comparison of results between studies. The same brand of
grapefruit juice was used in every study to minimize possible variability in the content of its
active ingredients. Relatively large amounts of grapefruit juice were used to uncover any
potential of the study drugs to interact with it. In some countries, quite a large portion of
households purchase grapefruit juice, and it may be consumed individually in variable amounts
on a daily basis. In these studies, the effect of grapefruit juice dose was also investigated.
Among all the volunteers, grapefruit juice intake was associated in only one subject with
gastrointestinal discomfort.
The volunteers fasted for at least one hour before administration of the study drugs to minimize
any possible effect of food on their absorption; during each study day a standardized lunch and
a light lunch were served.
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The doses of the drugs used were recommended daily doses. All of the study drugs were
administered only orally, as none were available as intravenous formulations. Use of
intravenous formulations would have allowed a more direct means of investigating
mechanisms by which grapefruit juice can alter pharmacokinetics, making it possible to
estimate total clearance and bioavailability of the drugs during different study phases.
However, on the basis of previous data, it seems likely that changes in the AUC of high-
clearance drugs with low bioavailability, e.g., simvastatin and buspirone, are primarily due to
alterations in their first-pass metabolism and to a lesser degree in their systemic clearance
(Masica et al. 2000). On the other hand, the AUC of intermediate-clearance drugs is more
sensitive to alterations in their systemic clearance during the hepatic elimination phase. A
single dose of study drug was administered in each study. Previous studies, in which the
CYP3A4 inhibitor has been given for a few days and then the CYP3A4 substrate in a single
dose, have predicted the susceptibility of CYP3A4 substrates, e.g., lovastatin and simvastatin,
to pharmacokinetic interactions with such drugs as itraconazole or erythromycin fairly reliably.
Both females and males were recruited as study volunteers. However, it was considered
unnecessary to balance each study in respect to gender because of the cross-over design.
Furthermore, in previous studies the menstrual cycle has not been found to affect the
metabolism of CYP3A4 substrates (Kashuba et al. 1998; Kharasch et al. 1997). Some of the
female subjects were using OCs that contained ethinyl estradiol, gestodene, desogestrel, or
levonorgestrel, potent mechanism-based inhibitors of CYP3A4 (Guengerich 1988; Guengerich
1990; Back et al. 1991). However, as previous data do not show OCs to have a major effect on
the pharmacokinetics of CYP3A4 substrates in vivo, probably because of the low amounts of
steroids in these products, use of OCs was not an exclusion criterion (Scavone et al. 1988;
Stoehr et al. 1984). In the present studies, OCs showed no consistent effect on pharmacokinetic
results. Regular smokers were not recruited into any of these studies.
The psychomotor effects of buspirone and of triazolam were measured by six and by four tests
validated and widely used for measurement of psychomotor effects of drugs. Before entering
the study, the subjects were properly trained to perform these tests to avoid any learning effect.
While the effects of benzodiazepines on the results of these tests are well known, buspirone
itself has shown previously only minor or no effects on the results (Smith and Misiak 1976;
Stone 1984; Seppälä et al. 1982; Greenblatt et al. 1994).
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The plasma concentrations of buspirone and of triazolam were measured by a sensitive gas
chromatographic method in Studies I and V, respectively; the between-day CV was satisfactory
for this method. In Study II, plasma cisapride concentrations were measured by HPLC.
Sensitivity and between-day CV were satisfactory. The serum concentrations of statins were
assayed by sensitive LC-MS-MS in Studies III, IV, and VI. The between-day CVs of these
methods were good or satisfactory. In addition, in Studies III and IV, serum HMG-CoA
reductase inhibitory activity was measured by nonspecific REA. With this method, the
between-day CVs were good or satisfactory.
2. Effects of grapefruit juice on the pharmacokinetics of buspirone
In this study, grapefruit juice increased the Cmax and AUC(0-∞) of buspirone about 4-fold and
9-fold. The tmax of buspirone was prolonged by grapefruit juice and the elimination t½ of
buspirone increased by about 50% in the grapefruit juice phase compared to the water phase.
The interaction of grapefruit juice with buspirone was subject to considerable interindividual
variability, the individual increase in Cmax ranging from 2-fold to nearly 16-fold and that in
AUC from 3-fold to 20-fold. Substantial changes in the pharmacokinetics of buspirone were
associated with only modest alterations in the pharmacodynamic results.
Buspirone is almost completely absorbed from the gastrointestinal tract. However, due to its
extensive first-pass metabolism, its bioavailability is only about 5% (Mayol et al. 1985).
Buspirone is oxidatively metabolized in the liver, yet the specific CYP enzymes involved
remain to be identified (Jajoo et al. 1990). However, the known CYP3A4 inhibitors
itraconazole, erythromycin, diltiazem, and verapamil have all considerably increased buspirone
plasma concentrations in vivo (Kivistö et al. 1997; Lamberg et al. 1998a). In the present study,
the effect of grapefruit juice on the pharmacokinetics of buspirone was smaller than that of
itraconazole but greater than that found for verapamil or diltiazem (Kivistö et al. 1997;
Lamberg et al. 1998a). In humans, CYP3A4 is extensively expressed not only in the liver but
also in the apical enterocytes of the small intestine (Kolars et al. 1992; Paine et al. 1997). Thus,
a large portion of the metabolism of buspirone may occur in the gut wall during the first pass.
Lown et al. have suggested that grapefruit juice inhibits CYP3A4-mediated first-pass
metabolism by direct inactivation of small intestinal CYP3A4 (Lown et al. 1997). Therefore, it
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is probable that the considerable increase in the mean AUC value of buspirone observed in this
study is due to a reduced gut first-pass metabolism caused by grapefruit juice. Findings in this
study give support to the assumption that the gut wall is an important site for the
biotransformation of buspirone, as it may be for some other CYP3A4 substrates with extensive
first-pass metabolism. The magnitude of change in the pharmacokinetics of buspirone caused
by grapefruit juice was almost the same as that in the pharmacokinetics of lovastatin, another
CYP3A4 substrate with low bioavailability (Kantola et al. 1998a).
The prolonged tmax of buspirone during the grapefruit-juice phase may reflect a delayed gastric
emptying caused by the juice. The tmax-increasing effect of grapefruit juice has been seen in
some but not all studies (Fuhr 1998). Lengthening of the elimination t½ of buspirone may also
be caused by postponed tmax or may represent a minor effect of grapefruit juice on the systemic
clearance of buspirone. Neither itraconazole nor the calcium-channel blockers verapamil and
diltiazem greatly prolonged the elimination t½ of buspirone (Kivistö et al. 1997; Lamberg et al.
1998a).
The considerably increased plasma buspirone concentrations during the grapefruit-juice phase
were associated with only slightly altered pharmacodynamic test results. The only significant
change compared to the water phase was seen in the subjective overall drug effect. Relatively
small changes in psychomotor test results in association with markedly increased buspirone
concentrations have been seen also in other studies (Kivistö et al. 1997; Lamberg et al. 1998a).
This can be in part explained by the logarithmic relationship between drug concentration and
effect. In addition, it may be that the classic psychomotor tests reflect more sensitively the
pharmacodynamic effects of benzodiazepines than those of buspirone. On the other hand, it
seems that high concentrations of buspirone are associated with increased frequency of adverse
effects (Kivistö et al. 1997; Lamberg et al. 1998a).
3. Effects of grapefruit juice on the pharmacokinetics of cisapride
This study demonstrated that repeated consumption of grapefruit juice considerably elevates
plasma concentrations of cisapride. The AUC and Cmax were increased by about 140% and 80%
after ingestion of grapefruit juice. In addition, the elimination t½ of cisapride was significantly
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increased by grapefruit juice. The grapefruit juice-cisapride interaction was, however, found to
be subject to considerable interindividual variation.
The oral bioavailability of cisapride is about 50%, due to first-pass metabolism (Van Peer et al.
1986; McCallum 1991). Recently it has been demonstrated that cisapride is biotransformed
mainly by CYP3A4 (Desta et al. 1999; Gotschall et al. 1999; Bohets et al. 2000). It is thus
likely that the considerable increase observed in the AUC of cisapride in the grapefruit-juice
phase of this study was caused by inhibition of CYP3A4. Inhibition of CYP3A4-mediated
metabolism occurred probably to a large extent during the first pass in the small intestine,
because the Cmax was increased by about 80%, whereas the increase in the elimination t½,
although significant, was only about 25%. Moreover, the changes in cisapride Cmax and in
AUC(0-∞) caused by grapefruit juice were correlated, whereas no such correlation was evident
between the elimination t½ and AUC(0-∞) of cisapride. The magnitude of the grapefruit juice-
cisapride interaction was clearly smaller than that of grapefruit juice-buspirone or of grapefruit
juice-simvastatin (Studies I and III). This is conceivable in the light of the bioavailabilities of
these drugs: 50% for cisapride but less than 5% for both buspirone and simvastatin; i.e.,
cisapride undergoes less extensive CYP3A4-mediated first-pass metabolism.
Cisapride has been a widely used drug and is generally well tolerated. However, concern has
recently been raised as to its safety because of an increasing number of reported cases in which
use of cisapride is associated with prolongation of the QT interval, ventricular tachycardia and
even death. In the majority of these cases, cisapride has been used in high doses or patients
have cardiac or renal disease or there has been concomitant use of CYP3A4 inhibitors like
imidazole antifungals and macrolide antibiotics (Wysowski and Bacsanyi 1996). It seems that
the increased risk for cisapride-induced arrhythmias is related to high cisapride concentrations.
In a study by van Haarst et al. (1998) combined use of cisapride (10 mg given four times a day)
and clarithromycin (500 mg twice a day) for 5 days caused 3-fold increases in cisapride
concentrations and prolonged the QTc interval significantly from that during cisapride
monotherapy. Furthermore, hypokalemia or administration of other QTc interval-prolonging
drugs together with cisapride may precipitate its arrhythmogenic effect. In vitro cisapride can
concentration-dependently block potassium channels in cardiac myocytes and thus prolong
repolarization time and QTc interval (Puisieux et al. 1996; Drolet et al. 1998). In this study, the
mean QTc interval was slightly but significantly prolonged from baseline during both treatment
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periods. However, despite the considerable increase in plasma concentrations of cisapride
caused by grapefruit juice, no difference was seen between the grapefruit juice and water
phases in the QTc interval. It is possible that long-term coadministration of grapefruit juice and
cisapride or use of a higher single dose of cisapride may have increased the effect of cisapride
on the QTc interval. In a recent study by Gross et al., a single dose of grapefruit juice increased
the AUC of cisapride by about 40% (1999) but had no QTc interval-increasing effect.
Based on such findings, the manufacturer of cisapride has recently warned against concomitant
use of cisapride with potent CYP3A4 inhibitors including grapefruit juice, and sale of
medicinal products containing cisapride was suspended in the USA, Canada, and Germany
during the year 2000.
4. Effects of grapefruit juice on the pharmacokinetics of simvastatin
Grapefruit juice greatly altered the pharmacokinetics of simvastatin. The mean AUC and Cmax
of simvastatin were 16- and 9-fold, respectively, in the grapefruit juice phase compared to
control values, and simvastatin acid AUC was increased about 7-fold.  Grapefruit juice
increased the AUC of active and total HMG-CoA reductase inhibitors 2.4-fold and 3.6-fold.
Simvastatin is an inactive lactone prodrug converted to the pharmacologically active
simvastatin acid by carboxyesterases and even non-enzymatically. Biotransformation of
simvastatin to other metabolites occurs mainly in reactions catalyzed by CYP3A4. In plasma,
simvastatin and its lactone metabolites are in dynamic equilibrium with their corresponding
hydroxy acid forms (Cheng and Jusko 1993). Bioavailability of simvastatin is low, and it is
probably extensively metabolized during the first pass not only in the liver but also in the gut
wall, where CYP3A4 is abundantly expressed (Kolars et al. 1992; Kivistö et al. 1996; Paine et
al. 1997). It is likely that the greatly increased Cmax and AUC values of simvastatin observed in
the present study were caused by inhibition of the small intestinal CYP3A4 by grapefruit juice.
This fits well the finding that grapefruit juice augments bioavailability of CYP3A4 substrates
by reducing protein expression of CYP3A4 in the small intestine (Lown et al. 1997). As
simvastatin acid is not prone to metabolism by CYP3A4, it is likely that its concentrations were
increased together with simvastatin concentrations due to the dynamic equilibrium between the
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two forms in the plasma. The changes observed in the AUC and Cmax values of active and total
HMG-CoA reductase inhibitors measured by REA were smaller than those of simvastatin. This
is probably caused in the grapefruit-juice phase by reduced production of metabolites of
simvastatin which possess HMG-CoA reductase inhibitory activity. Unlike the Cmax and AUC,
the elimination t½ of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors
remained essentially unaltered. This can be explained by the predominantly intestinal effect of
grapefruit juice and also by the pharmacokinetic properties of simvastatin: it is a high-
extraction drug metabolized to a large extent during the first pass, its systemic clearance
insensitive to the inhibition of the CYP3A4 enzyme. The greatly increased AUC value of
simvastatin in this study may also at least in part be explained by inhibition of the small
intestinal P-glycoprotein. Simvastatin may be a substrate for P-gp, just as the structurally
closely related lovastatin has been found to be (Kim et al. 1999). In vitro, components in
grapefruit juice inhibit P-gp (Takanaga et al. 1998; Eagling et al. 1999), but to date it has
remained unclear to what degree grapefruit juice affects P-gp activity in vivo. In the study by
Lown et al. (1997), grapefruit juice did not alter protein expression of P-gp in the small
intestine. However, it is possible that grapefruit juice can in other ways alter its function.
With the same brand of grapefruit juice and the identical dosing scheme of juice used in both
studies, grapefruit juice increased the AUC and Cmax of simvastatin (Study III) somewhat more
than those of buspirone (Study I). The estimated bioavailability of both of these drugs is less
than 5%. Simvastatin and probably also buspirone are predominantly biotransformed by
CYP3A4 (Prueksaritanont et al. 1997; Kivistö et al. 1997). The difference in the magnitude of
change in pharmacokinetics of simvastatin and buspirone may be partially explained by the
large interindividual variation in the amount of expressed CYP3A4 in the liver and small
intestine and by the relatively small number of study subjects. Three subjects took part in both
Study I and III. Interestingly, for one of these subjects the increase in the AUC of simvastatin
was 38-fold and in the AUC of buspirone 20-fold. Thus, a relatively constant individual
susceptibility even to drastic changes in drug metabolism due to CYP3A4 inhibition by
grapefruit juice may exist.
Lovastatin, like simvastatin, is an HMG-CoA reductase inhibitor that has low bioavailability
and undergoes CYP3A4-mediated metabolism (Jacobsen et al. 1999). Not unexpectedly, the
magnitude of interaction of grapefruit juice with simvastatin and with lovastatin is very similar.
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The same amount of grapefruit juice as in Study III increased the AUC of lovastatin 15-fold
(Kantola et al. 1998a). In that study the effect of grapefruit juice on HMG-CoA reductase
inhibitors was not determined. However, due to the very similar pharmacokinetic properties of
simvastatin and lovastatin, it is probable that the results in that study and the present one would
have resembled each other also in this respect.
The effect of grapefruit juice on the pharmacokinetics of simvastatin is nearly as great as that of
itraconazole and greater than that of erythromycin or verapamil (Neuvonen et al. 1998; Kantola
et al. 1998b). In reported cases of myopathy during administration of simvastatin, the patient
had often also taken potent CYP3A4 inhibitors (Schmassmann-Suhijar et al. 1998; Jacobson et
al. 1997). It seems that an increase in risk for rare but serious adverse effects of HMG-CoA
reductase inhibitors such as myopathy and rhabdomyolysis is associated with high drug doses
and high HMG-CoA reductase inhibitory activity (Tobert al. 1988). As the present studies
demonstrate, grapefruit juice can drastically increase concentrations of certain orally ingested
CYP3A4 substrates. For any given subject, prediction of the magnitude of the interaction is
difficult, given the wide interindividual variation in expression and activity of CYP3A4. Thus,
in some individuals repeated ingestion at least of high amounts of grapefruit juice may cause an
elevation of serum simvastatin concentrations that can increase the risk for adverse-effects of
simvastatin.
5. Effects of grapefruit juice on the pharmacokinetics of atorvastatin and pravastatin
Grapefruit juice increased the AUC of atorvastatin acid and atorvastatin lactone about 2.5-fold
and 3.3-fold, and the AUC values of active and total HMG-CoA reductase inhibitors were
higher during the grapefruit juice phase than during the water phase. The AUC of the principal
active metabolite 2-hydroxyatorvastatin and its lactone form were reduced by grapefruit juice,
and the elimination half-lives of both atorvastatin acid and 2-hydroxyatorvastatin and their
respective lactones significantly prolonged. In contrast, grapefruit juice had no effect on the
AUC, Cmax, or elimination t½ of pravastatin, whether measured by LC-MS-MS or REA.
Atorvastatin is an HMG-CoA reductase inhibitor administered as the calcium salt of the active
hydroxy acid form of atorvastatin acid. Its bioavailability after oral administration is about
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12%. Atorvastatin is extensively metabolized and has at least two active metabolites, 2-
hydroxyatorvastatin and 4-hydroxyatorvastatin, which are formed by CYP3A4. It has been
estimated that 70% of the HMG-CoA reductase inhibitory activity of atorvastatin is accounted
for by its metabolites (Lea and McTavish 1997).
Grapefruit juice increased the concentration of atorvastatin considerably less than that of
simvastatin in Study III. This most probably reflects the less extensive CYP3A4-mediated
atorvastatin first-pass metabolism compared with that of simvastatin. However, that the
magnitude of the effect of grapefruit juice on the pharmacokinetics of atorvastatin was nearly
as great as that of itraconazole suggests the importance of the small intestine and CYP3A4 in
atorvastatin first-pass metabolism (Kantola et al. 1998c). In addition to grapefruit juice and
itraconazole, the known CYP3A4 inhibitor erythromycin has been found significantly to
increase atorvastatin concentrations (Siedlik et al. 1999). During the grapefruit-juice phase, 2-
hydroxyatorvastatin and 2-hydroxyatorvastatin lactone concentrations were significantly
reduced. This most likely resulted from the reduced CYP3A4-mediated formation of 2-
hydroxyatorvastatin from atorvastatin caused by grapefruit juice.
Pravastatin is a hydrophilic HMG-CoA reductase inhibitor administered as a sodium salt of the
active pravastatin acid. About 34% of the pravastatin dose is absorbed after oral administration,
and approximately 50% of this absorbed dose undergoes presystemic metabolism, the oral
bioavailability of pravastatin being about 20%. Pravastatin is metabolized by several enzymes
to at least 17 different metabolites that contribute less than does the parent pravastatin to HMG-
CoA reductase inhibitory activity. In the present study, grapefruit juice very little affected the
pharmacokinetics of parent pravastatin or HMG-CoA reductase inhibitors. Moreover, in
previous studies the known CYP3A4 inhibitors itraconazole, erythromycin, and diltiazem did
not much affect the pharmacokinetics of pravastatin  (Neuvonen et al. 1998; Donahue et al.
1998; Azie et al. 1998). However, cyclosporine has been found to increase pravastatin
concentrations significantly (Regazzi et al. 1994; Olbricht et al. 1997). It has been hypothesized
that this interaction between pravastatin and cyclosporin may be caused at least in part by
cyclosporine through the inhibition of membrane transporter proteins such as P-gp. For
instance, inhibition of P-gp in the gut wall may increase serum pravastatin concentrations. In
any case, it has been proposed that inhibition of CYP3A4 does not interfere with pravastatin
metabolism to such a degree that this would be of clinical relevance (Jacobsen et al. 1999). It is
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thus conceivable that grapefruit juice did not increase serum concentrations of pravastatin in
this study because the predominant mechanism of action of grapefruit juice is CYP3A4
inhibition.
6. Effect of grapefruit juice dose on the interaction between grapefruit juice and
triazolam
In the present study, in which the effect of grapefruit juice dose on the pharmacokinetics and
pharmacodynamics of the orally administered CYP3A4 substrate triazolam was investigated by
means of a randomized four-phase cross-over study, a single 200-ml dose of normal- or double-
strength grapefruit  juice increased the AUC of triazolam by about half, and repeated ingestion
of double-strength grapefruit juice led to an increase of 150% in the AUC of triazolam. The
Cmax of triazolam was increased 40 to 50% during the three grapefruit-juice phases compared
with that of the water phase. The elimination t½ of triazolam was increased by 54% during the
repeated ingestion of grapefruit juice, but remained unaffected by single-dose grapefruit juice.
Pharmacodynamic effects of triazolam were significantly greater during the multiple-dose
grapefruit juice phase than the water phase.
Only a few studies have addressed the role of grapefruit juice dose in grapefruit juice-drug
interactions. In a study by Edgar et al. (1992) 200 ml of normal-strength grapefruit juice
affected the pharmacokinetics of felodipine as much as did double- strength juice at 200 ml.
Thus, our results concerning the effects of a single dose of normal- and double-strength
grapefruit juice on the Cmax and AUC of triazolam are in accordance with the findings of Edgar
et al. The effect of repeated ingestion of grapefruit juice on felodipine pharmacokinetics was
investigated by Lown et al. (1997), who found that a single dose (250 ml) of grapefruit juice
increased the AUC and Cmax of felodipine by 116% and 225%, respectively; grapefruit juice
ingested three times daily for 5 days increased felodipine AUC and Cmax by 211% and 335%.
Our findings are in line with theirs, demonstrating that repeated ingestion of grapefruit juice
has a greater effect on the AUC of CYP3A4 substrates than does one single dose. Lown et al.
found that multiple-dose administration of grapefruit juice inactivated small intestinal CYP3A4
significantly more than did a single dose of juice. Thus it appears that inhibition of CYP3A4-
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mediated metabolism accumulates when grapefruit juice is ingested repeatedly, probably
because the rate of regeneration of the active enzyme is exceeded by its rate of inactivation.
Lown et al. did not report their elimination t½ of felodipine, but the activity of their hepatic
CYP3A4 was unaffected by multiple-dose grapefruit juice, as measured by erythromycin breath
test. On the other hand, in our study the elimination t½ of triazolam after multiple-dose
grapefruit juice was significantly prolonged. Assuming that the volume of distribution of
triazolam was unchanged, prolongation of the elimination t½ of triazolam suggests that chronic
administration of grapefruit juice can reduce systemic clearance of triazolam, probably by
inhibiting the hepatic CYP3A4. It appears that the increase in triazolam AUC during the
multiple-dose grapefruit juice phase compared to the single-dose phases can be explained by
decreased hepatic elimination of triazolam, because the t½ but not Cmax of triazolam was
increased by the repeated ingestion of grapefruit juice. In previous studies, grapefruit juice has
increased the Cmax and AUC of orally administered CYP3A4 substrates, but when
administered intravenously has not affected their pharmacokinetics (Ducharme et al. 1995b;
Kupferschmidt et al. 1995; Lundahl et al. 1997). However, in those studies a single dose of
grapefruit juice was ingested once or twice in association with drug administration.
Coadministration of cisapride with a single dose of grapefruit juice has increased cisapride
AUC by about 50% without altering the elimination t½ of cisapride (Gross et al. 1999). In our
Study III, both the AUC and elimination t½ of cisapride were increased significantly after
repeated ingestion of grapefruit juice. In a recent preliminary report of Veronese et al. (1999),
ingestion of grapefruit juice three times daily for 3 days increased the AUC of intravenously
administered midazolam 5.9-fold compared with that of their control, and activity of the
hepatic CYP3A4 was inhibited by grapefruit juice as measured by erythromycin breath test.
Thus, it appears that during repeated ingestion, active ingredients in grapefruit juice, e.g., the
lipophilic compounds furanocoumarins, may reach the systemic circulation in concentrations
sufficient to inhibit both the small intestinal and the hepatic CYP3A4.
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7. Duration of effect of grapefruit juice on the pharmacokinetics of simvastatin
In this study the aim was to investigate how long after ingestion of grapefruit juice its effect on
the pharmacokinetics of simvastatin lasts. Simvastatin, a substrate for CYP3A4, was used as
the model drug, as it has proven to be very sensitive to CYP3A4 inhibition (Study III;
Neuvonen et al. 1998; Kantola et al. 1998b). Grapefruit juice was ingested on 3 consecutive
days to reveal its maximal duration of effect on the pharmacokinetics of the CYP3A4 substrate.
Administration of multiple-dose grapefruit juice with simvastatin increased the AUC of
simvastatin 13.5-fold compared with the water phase. After an interval of 24 hours between
ingestion of the final dose of grapefruit juice and intake of simvastatin, the effect of grapefruit
juice was reduced to such a degree that the AUC of simvastatin was 2-fold that of the water
phase. When simvastatin was given 3 days after cessation of grapefruit juice intake, the AUC
of simvastatin was less than 50% greater than for the water phase. After an interval of 7 days
between cessation of  grapefruit juice intake and intake of simvastatin, no change occurred in
the AUC of simvastatin. The mean change in the AUC value of simvastatin acid induced by
grapefruit juice was smaller than the change in the AUC value of simvastatin, this increase
vanishing in 3 days. This is in line with the previous observation that simvastatin acid is not
readily metabolized by CYP3A4.
A previous study has shown that a single dose of grapefruit juice may increase felodipine Cmax
and AUC for up to 24 and 10 hours (Lundahl et al. 1995). In another study, volunteers were
given a single oral dose of nisoldipine with water, with grapefruit juice, or 14 to 96 hours after
a 7-day period of thrice daily ingestion of grapefruit juice (Takanaga et al. 2000a). Grapefruit
juice affected nisoldipine pharmacokinetics for at least 3 days after the last intake of juice.
Taking into consideration previous results of the accumulating effect of repeated intake of
grapefruit juice, our present findings seem to be in line with those of these two studies.
Recently, Rogers et al. (1999) published a study in which volunteers ingested grapefruit juice
for 3 consecutive days during breakfast and received 40 mg lovastatin in the evening. The AUC
of lovastatin was increased about 1.9-fold by the grapefruit juice, thus demonstrating the
significance of time-interval between the grapefruit juice and CYP3A4 substrate ingestion in
the extent of grapefruit juice-drug interaction.
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According to Lown et al. (1997) grapefruit juice alters the pharmacokinetics of CYP3A4
substrates by inactivating the small intestinal CYP3A4. Thus, duration of grapefruit-juice effect
depends on the rate of de novo synthesis of the small intestinal CYP3A4. In the present study it
was roughly estimated that the t½ of effect of grapefruit juice on the AUC of simvastatin was
shorter during the first day after grapefruit juice ingestion, 7 to 8 hours, than during the
following days, 30 to 40 hours. Takanaga et al. constructed a pharmacokinetic model based on
the results of two previous studies (Lundahl et al. 1995; Lundahl et al. 1998). According to this
model, the terminal t½ of CYP3A4 was 8 hours (Takanaga et al. 2000b). In the subsequent
study with nisoldipine, the terminal t½ of CYP3A4 was calculated to be 30 hours, i. e., at 3-fold
to 4-fold greater than the initial value (8 hours). The authors speculate that one explanation for
this divergence of results might be the different length of times of data collection between these
two studies (Lundahl et al. 1995; Takanaga et al. 2000a). The intake scheme for grapefruit juice
was also different between the two studies. On the basis of these studies it appears that a large
portion of the small intestinal CYP3A4 is regenerated, and most of the effect of both single-
and multiple-dose grapefruit juice disappears within 24 hours after juice intake.
Previous studies have assumed that the predominant mechanism of action of grapefruit juice is
inhibition of CYP3A4-mediated first-pass metabolism mainly in the intestinal wall. On the
other hand, one can speculate as to the contribution of this possible inhibition of the hepatic
CYP3A4 or P-gp to duration of the grapefruit juice effect. In particular, it appears that the
intestinal  and hepatic CYP3A4 are not coregulated (Lown et al. 1994). Differences in the
catalytic activity and relative amounts of CYP3A4 in the liver and intestine may constitute one
cause of the interindividual variation observed in duration of the grapefruit juice effect.
However, in one recent study, intravenous diltiazem did not affect the AUC of lovastatin, thus
supporting previous proposals that the small intestine is the main site of the first-pass
metabolism of lovastatin and thus probably also of simvastatin (Masica et al. 2000). The
smaller the AUC initially, the larger the increase due to CYP3A4 inhibition caused by
grapefruit juice (Lown et al. 1997).
There are studies suggesting that by inhibiting P-gp, grapefruit juice may alter significantly the
pharmacokinetics of orally administered drugs (Takanaga et al. 1998; Edwards et al. 1999).
However, Eagling et al. (1999) concluded that the in vivo effects of grapefruit juice are only to
a minor extent caused by modulation of P-gp function.  Furthermore, our results with
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simvastatin are in line with those of  Lundahl et al. (1995) and Takanaga et al. (2000a), who
used dihydropyridine calcium-channel blockers as the model drugs, which are not good
substrates for P-gp. Thus, in the present study, relationships between time after intake of
grapefruit juice and its effects can probably be explained by inhibition of CYP3A4 of different
degrees.
8. Clinical implications
Grapefruit juice can substantially interfere with the pharmacokinetics of some concomitantly
ingested CYP3A4 substrates. CYP3A4 is a major drug-metabolizing enzyme in humans,
participating in the metabolism of about half the drugs used therapeutically. Of the drugs
studied in this series of investigations, simvastatin and cisapride seem to have the potential for
clinically relevant pharmacokinetic interactions with grapefruit juice. Both drugs undergo
considerable CYP3A4-mediated first-pass metabolism and produce dose-dependent and, even
serious adverse effects. High serum concentrations of simvastatin increase risk for myopathy,
and cisapride prolongs the QT interval in a concentration-dependent manner. Further, at least in
high doses, grapefruit juice may increase risk of adverse effects of buspirone and atorvastatin.
That the pharmacokinetics of CYP3A4 substrates are subject to considerable interindividual
variation makes it difficult to predict the magnitude of the grapefruit juice effect for any
individual patient. The unpredictability of the effect can be further increased by variation in the
content of the active components in grapefruit juice. It is recommended to refrain from
simultaneous use of grapefruit juice with CYP3A4 substrates that have a substantial first-pass
metabolism and a narrow therapeutic range. If the dose-response curve is flat, reduction of drug
dose can be applied. It has been suggested that if an interaction between grapefruit juice and a
CYP3A4 substrate is not excluded in a pharmacokinetic study, and this drug is contraindicated
for use with itraconazole and erythromycin, then it should not be taken along with grapefruit
juice (Kane and Lipsky 2000). Because of the additive CYP3A4 inhibitory effect, caution
should be exercised if the patient is already using drugs that are considered moderate CYP3A4
inhibitors, e.g., diltiazem or verapamil.
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The oral bioavailability of CYP3A4 substrates with extensive intestinal first-pass metabolism
may be enhanced by their coingestion with grapefruit juice (Fuhr 1998; Ameer and Weintraub
1997). In the case of cyclosporine, for example, it may thus be possible to reduce doses and
achieve significant cost savings. However, because of the unpredictability of the grapefruit
juice effect, appropriate dose adjustments may necessitate more frequent cyclosporine blood-
concentration monitoring, and this can reduce any savings gained.
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CONCLUSIONS
From the six studies the following conclusions can be drawn:
1.  Grapefruit juice, particularly in multiple doses, may increase plasma concentrations of some
CYP3A4 substrates with low oral bioavailability almost as strongly as does the potent CYP3A4
inhibitor itraconazole. Grapefruit juice probably acts mainly by inhibiting CYP3A4-mediated
first-pass metabolism in the small intestine. However, some effects of grapefruit juice may
result in part from modulation of the function of P-glycoprotein.
2.  The magnitude of the effect of grapefruit juice on the pharmacokinetics of a CYP3A4
substrate is related to the extent of its CYP3A4-mediated first-pass metabolism.
3.  Multiple-dose ingestion of grapefruit juice affects CYP3A4 substrate pharmacokinetics
significantly more than does a single dose, and may also inhibit hepatic CYP3A4 during the
elimination phase.
4.  The effect of multiple-dose grapefruit juice on the pharmacokinetics of CYP3A4 substrate
with extensive first-pass metabolism subsides markedly within 24 hours and disappears
completely within 3 to 7 days after termination of ingestion of  grapefruit juice.
5.  Concomitant use of grapefruit juice with CYP3A4 substrates should be avoided if these are
subject to extensive first-pass metabolism and have a narrow therapeutic range; alternatively,
the dose of the CYP3A4 substrate drugs should be reduced accordingly.
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